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We identified and functionally characterized yeast fRMsr homolog which showed 
specificity for reduction of free Met-R-SO and contributed to oxidative stress resistance 
of yeast cells. We further identified three conserved Cys which participate in catalysis 
through disulfide exchange. Evolutionary analyses revealed that the occurrence of fRMSr 
is restricted to unicellular organisms.  
We further found that mammalian MsrA can reduce free Met-S-SO, whereas 
MsrBs do not reduce free Met-R-SO. Consistent with these findings and the lack of 
fRMsr, mammalian cells could not grow in media that replaced Met with Met-R-SO. 
However, they grew in the presence of free Met-S-SO, which was reduced by MsrA. 
Expression of yeast fRMsr in mammalian cells supported the growth of mammalian cells 
on Met-R-SO, increased resistamce to oxidative stress, and affected expression levels of 
proteins that are regulated by Met availability.        
We extended the finding of deficiency in free Met-R-SO reduction in mammals to 
examine the ability of Msrs to reduce compounds containing methylsulfinyls. 
 Methylsulfide group has a prochiral sulfur, resulting in two diastereomers upon 
sulfoxidation. We found that methylsulfinyls in sulmazole sulfoxide, triclabendazole 
sulfoxide, and mesoridazine could be stereospecifically reduced by MsrA, but MsrB and 
fRMsr were not active. We also found that dimethylsulfoxide (DMSO), which has a 
methylsulfinyl group, can only be reduced by MsrA.  
To examine the role of Met in aging, we performed lifespan analyses in fruit flies. 
There was no difference in lifespan of flies maintained on restricted (0.1 mM Met) and 
regular (1 mM) Met diets. Instead, we observed uncoupling between reproduction and 
longevity. A popular theory of aging suggests that dietary restriction is inversely 
proportional to reproduction due to nutritional redistribution of resources from egg 
generation to somatic maintenance, but we found that this theory did not follow our data 
that are based on variation in Met concentration.  
Overall, our studies characterized all three known types of methionine sulfoxide 
reductase and uncovered biological significance of free methionine sulfoxide reduction 
and its deficiency in mammals. 
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1.1. Oxidation of methionine by reactive oxygen species  
Molecular oxygen is indispensable for survival of aerobic organisms, but its use is 
also associated with generation of reactive oxygen species (ROS) by mitochondrial 
respiration, NADPH-oxidation and other processes [1]. ROS may often damage 
macromolecules such as proteins, lipids, and nucleic acids and thus contribute to the 
incidence of many disorders such as cancer, neurodegeneration, diabetes, and other 
maladies [2-5]. Moreover, numerous lines of evidence strongly suggest that damage 
initiated by ROS may lead to decay of health and accelerate the aging process.      
 Amino acids in either free or protein-based forms are also exposed to oxidative 
modifications by ROS. Together with Cys and tryptophan, Met is the amino acid most 
highly susceptible to oxidation by ROS. Met is oxidized to form a mixture of Met-R-SO 
and Met-S-SO and this modification may affect structure and function of proteins [6, 7].  
 
1.2. Functions of methionine sulfoxide reductases 
To protect against ROS damage, organisms evolved defense systems such as 
glutathione peroxidase (GPx), superoxide dismutase (SOD), catalase, thioredoxin 
reductase (TR), and many other antioxidant enzymes [8-13]. To counteract Met oxidation 
by ROS, organisms also evolved methionine sulfoxide reductases (Msrs), which are thiol 
oxidoreductases that exists ubiquitously in most living organisms [14-17]. 
Msrs can reduce either Met-R-SO or Met-S-SO to Met. Based on this function, 
these enzymes play important roles in protecting organisms from oxidative stress. Msrs 
are known for their functions in maintaining redox homeostasis, repairing damaged 
proteins, and increasing oxidative stress resistance. Furthermore, numerous studies 
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showed that these functions of Msrs can be important factors that ameliorate certain 
diseases by normalizing redox homeostasis [16-20]. 
        
1.3. Three types of methionine sulfoxide reductase 
The first Msr enzyme, MsrA, was discovered some 30 years ago. It was found 
that this enzyme can restore the function of oxidized ribosomal protein L12 in E. coli 
[21]. After this initial finding, Msrs were investigated from a variety of organisms, new 
forms were discovered, and currently these enzymes can be divided into three large 
groups according to their substrate specificity and family clustering. MsrA is specific for 
the reduction of free and protein-based Met-S-SO. This protein is the only known enzyme 
capable of reducing Met-S-SO [22-25], but it can also reduce other compounds such as 
N-acetyl-methionine-S-sulfoxide, dimethyl sulfoxide, ethionine-S-sulfoxide, S-sulindac, 
S-sulforaphane, etc. [26-28]. It was found that MsrA exist in a selenoprotein form in 
some lower organisms, such as green algae and some bacteria, wherein it utilizes 
catalytic selenocysteine (Sec) in place of Cys [29-30].  
A second Msr, known as MsrB (described previously as SelR or SelX), is specific 
for the reduction of protein-based Met-R-SO, but also, with low efficiency, of free Met-
R-SO. For example, catalytic efficiency of E. coli MsrB for reduction of free Met-R-SO 
is 1000-fold lower than that of E. coli MsrA for free Met-S-SO. In addition, when the 
MsrB gene was disrupted in E. coli, specific activity of cell extract for reduction of free 
Met-R-SO was essentially unchanged [31, 32], whereas mutation of another Msr gene 
(see below) in yeast resulted in reduced activity with this substrate [33].  
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In mammals, there are three MsrB proteins, including MsrB1, MsrB2, and MsrB3. 
All three contain Zn, coordinated by two CxxC motifs (i.e., two Cys separated by two 
residues), which stabilizes MsrB structure. Of these three enzymes, MsrB1 is a 
selenoprotein that contains Sec in the place of the catalytic Cys residue normally present 
in other MsrBs [35, 36].  
A third Msr type, fRMsr, was only recently discovered [37] and it catalyzes the 
reduction of free Met-R-SO [33, 34, 37]. This enzyme is a GAF-domain-containing 
protein and is highly specific for its substrate (i.e., it does not act on protein-base 
sulfoxides) [33, 37, 38]. Interestingly, comparative genomic analysis of fRMsr revealed 
that its occurrence is limited to unicellular organisms, whereas multicellular organisms, 
including mammals, lack this protein [33, 37]. This observation suggested that fRMsr 
was lost during evolution in mammals, which currently lack this function, i.e., they are 
deficient in the reduction of free Met-R-SO. 
The three Msrs support oxidative protein repair and methionine metabolism 
functions by reducing free and protein-based methionine-R,S-sulfoxides. The key 
function of Msr is to repair oxidatively damaged proteins, in which ROS oxidized 
methionine residues. This oxidation may interfere with protein function, because it leads 
to an increased negative charge and size, and consequently may result in structural 
changes and loss of function [6, 7, 39]. In addition, Msrs may work indirectly as ROS 
scavengers through cyclic oxidation and reduction of methionine and methionine 
sulfoxide residues. The methionine/Msr system may assist other redox systems, such as 
thioredoxin and glutathione systems, in maintaining cellular redox homeostasis. This idea 
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is consistent with the data showing that deficiency in various Msrs results in oxidative 
stress [14, 16, 40, 41]. Methionine sulfoxides and Msrs may also play a role in sensing 
altered redox status and regulating certain proteins. Recently, it was shown that CaMKII 
(calcium/calmodulin (Ca2+/CaM)-dependent protein kinase II) was activated by oxidation 
of its methionine residue in the regulatory domain in the absence of Ca2+/CaM and that 
this activation could be reversed by MsrA [42]. In addition, human large conductance 
Ca2+-activated K channels (BKCa or Slo), E. coli Ffh, human potassium channel HERG1, 
and calmodulin are known to be regulated by oxidation of methionine and repair activity 
of Msrs [43-45]. Along with these Msr functions, there were several reports showing that 
MsrA knockout mice exhibit a tip-toe walking behavior consistent with cerebellar 
dysfunction [46], enhanced neurodegeneration in hippocampus [47], and impaired 
dopamine regulation [48]. However, the specific link between Msrs and 
neurodegenerative diseases remains poorly understood.  
 
1.4. Catalysis by different type of methionine sulfoxide reductases 
Mammalian MsrA has three conserved Cys, which participate in catalysis as 
catalytic and resolving Cys. A sulfenic acid intermediate at the catalytic Cys is generated 
when this residue attacks the sulfur of Met-S-SO and then thiol-disulfide exchange 
involving two resolving Cys leads to a disulfide bond on the protein surface, which is 
ultimately reduced by thioredoxin or dithiothreitol (DTT) [49]. Recently, it was proposed 
that yeast fRMsr also has three conserved Cys that follow a similar sulfenic acid/thiol-
disulfide exchange mechanism. In addition, the thioredoxin system can function in 
recycling fRMsr like it does in the case of MsrA. A difference between MsrA and fRMsr 
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involves accessibility of the substrate. Yeast fRMsr has a narrow binding pocket, which 
limits access to bulky substrates. This may explain differences in substrate specificity 
between MsrA and fRMsr, even though the overall catalytic process involving catalytic 
and resolving Cys is similar in these enzymes [33, 37]. 
MsrB1 has one conserved Cys in the N-terminal portion and the catalytic Sec in 
the C-terminal region. During catalysis, Sec forms a selenenic acid intermediate by 
attacking the sulfur of Met-R-SO. This intermediate then rearranges into selenenylsulfide 
with the help of the resolving Cys and is finally reduced by thioredoxin [50]. In contrast, 
MsrB2 and MsrB3 have only one conserved Cys and appear to have evolved a different 
catalytic mechanism for the reduction of their sulfenic acid intermediate (i.e., without 
disulfide formation between catalytic and resolving Cys), which is reduced directly by 
thioredoxin [50-52]. Although thioredoxin is the most important reductant for Msrs, it 
was shown that thioredoxin-independent Msr reduction is also possible [19-20]. For 
example, thionein, selenocystamine, and CDP32 could be used for the reduction of 
human MsrB2 and MsrB3, and such thioredoxin-independent reaction may even be more 
efficient than that involving thioredoxin.  
 
1.5. Selenoproteins and catalytic benefits of selenocysteine utilization 
Selenoproteins exist in organisms in all three domains of life. Selenium is inserted 
into these proteins co-translationally in the form of selenocysteine, in response to UGA 
codon. Selenocysteine insertion is dependent on the presence of a stem-loop structure, 
known as the SECIS (selenocysteine insertion sequence) element, in the 3’-untranslated 
regions (UTR) of selenoprotein genes. Selenium is essential in mammals because of its 
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occurrence in selenoproteins. These proteins have various functions and show widely 
different knockout phenotypes. For example, glutathione peroxidase 4 (GPx4) reduces 
lipid peroxides and its knockout in mice results in embryonic lethality [53]. Another 
selenoprotein, Selenoprotein P (SelP), transports selenium from liver to brain, thyroid 
gland, kidney, testis and likely other organs. Without SelP, a much higher selenium 
intake is needed to support selenoprotein synthesis [54-56]. Selenoprotein N (SelN) is a 
protein of unknown function and mutations in this gene are linked to various muscular 
diseases, such as rigid spine muscular dystrophy [57]. Many of the 25 human 
selenoproteins contribute to the regulation of redox homeostasis, but the functions of 
several proteins are not known. Perhaps the best studied selenoprotein families are 
glutathione peroxidases and thioredoxin reductases. There are 5 selenoprotein GPxs in 
humans and 4 in mice, which function as thiol-dependent peroxidases. Thioredoxin 
reductases 1, 2, and 3 regulate cellular redox homeostasis by controlling the redox state 
of thioredoxins [58]. Selenoprotein W (SelW) and selenoprotein K (SelK) might also 
play a role in redox regulation. For example, SelW binds glutathione and its 
overexpression increases resistance to oxidative stress in CHO cells and H1299 cancer 
cells in a glutathione-dependent manner [59, 60]. Overexpression of SelK reduces 
intracellular ROS levels and protects cardiomyocytes from oxidative stress-induced 
toxicity [61]. 
Like other functionally characterized selenoproteins, MsrB1 is an oxidoreductase. 
Sec in this enzyme supports high catalytic efficiency of MsrB1 (>100-fold higher than 
that of the corresponding Cys-containing mutant) [35, 62, 63]. This enhancement of 
activity was also demonstrated for a Sec-containing MsrA from Chlamydomonas [30]. 
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Thus, Sec, strategically positioned in the active site, is a key catalytic residue, whereas its 
replacement with Cys leads to a significant drop or loss of catalytic activity. Similar 
observations were also made with iodothyronine deiodinase in oocytes [64, 65] and 
clostridial glycine reductase selenoprotein A [64, 66] 
However, Sec is not always beneficial under physiological conditions. When the 
catalytic Cys in MsrB2 and MsrB3 was replaced with Sec, activities of these enzymes 
were increased up to 100-fold in the presence of DTT as a reducing agent, but these 
proteins were not active with thioredoxin. One possibility is that a selenenic acid 
intermediate could not be efficiently reduced by thioredoxin and therefore the enzymes 
could not be regenerated for the next catalytic cycle, whereas a selenenylsulfide bond, 
formed between catalytic Sec and resolving Cys residues, was reducible by thioredoxin. 
This hypothesis was recently supported by the studies on a natural Sec-containing MsrA 
and an artificial selenoprotein MsrB from Clostridium sp., an anaerobic bacterium [29]. It 
was shown that these proteins have catalytic advantage by incorporating Sec as the 
catalytic residue, but they could not be reduced by thioredoxin, suggesting that the 
selenenic acid intermediate requires other reductants under physiological conditions.  
On the other hand, the use of Sec in MsrB and MsrA is rare when viewed from 
the evolutionary perspective. The absolute majority of these enzymes are Cys-containing 
proteins, and many of these are highly efficient in standard in vitro assays. Interestingly, 
Msrs are absent in many hyperthermophilic organisms because at higher temperatures, 
methionine sulfoxide reduction does not require catalysis. By the same token, 
selenoprotein Msrs might be needed under conditions when their Cys-containing 
counterparts are ineffective.  
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CHAPTER 2 
 
Functional analysis of free methionine-R-sulfoxide reductase from 
Saccharomyces cerevisiae 
 
Note: The results described in this chapter have been published and Lee, B. C. 
contributed to measuring fRMsr activity and identifying catalytic process through 
experimental way (Fig. 2.11. and 2.17.).  
The authors and title of the paper are: 
*Le, D. T., *Lee, B. C., Marino, S. M., Zhang, Y., Fomenko, D. E., Kaya, A., 
Hacioglu, E., Kwak, G. H., Koc, A., Kim, H. Y., and Gladyshev, V. N. (2009) Functional 
Analysis of Free Methionine-R-Sulfoxide Reductase from Saccharomyces Cerevisiae. J. 
Biol. Chem. 284, 4354-4364. 
 
*: Equal contribution 
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2.1. Abstract 
Msrs are oxidoreductases that catalyze thiol-dependent reduction of oxidized 
methionines. MsrA and MsrB are the best known Msrs that repair Met-S-SO and Met-R-
SO residues in proteins, respectively. In addition, an Escherichia coli enzyme specific for 
free Met-R-SO, designated fRMsr, was recently discovered. In this work, we carried out 
comparative genomic and experimental analyses to examine occurrence, evolution and 
function of fRMsr. This protein is present in single copies and two mutually exclusive 
subtypes in about half of prokaryotes and unicellular eukaryotes, but is missing in higher 
plants and animals. A Saccharomyces cerevisiae fRMsr homolog was found to reduce 
free Met-R-SO, but not free Met-S-SO or dabsyl-Met-R-SO. fRMsr was responsible for 
growth of yeast cells on Met-R-SO, and the double fRMsr/MsrA mutant could not grow 
on a mixture of methionine sulfoxides. However, in the presence of methionine, even the 
triple fRMsr/MsrA/MsrB mutant was viable. In addition, fRMsr deletion strain showed an 
increased sensitivity to oxidative stress and a decreased lifespan, whereas overexpression 
of fRMsr conferred higher resistance to oxidants. Molecular modeling and cysteine 
residue targeting by thioredoxin pointed to Cys101 as catalytic and Cys125 as resolving 
residues in yeast fRMsr. These residues as well as the third Cys, resolving Cys91, 
clustered in the structure, and each was required for the catalytic activity of the enzyme. 
The data show that fRMsr is the main enzyme responsible for the reduction of free Met-
R-SO in S. cerevisiae. 
 
2.2. Introduction 
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Among the 20 common amino acids in proteins, Met and Cys are the residues 
most susceptible to oxidation by ROS. Upon oxidation, Met forms a diastereomeric 
mixture of Met-S-SO and Met-R-SO. Met-S-SO and Met-R-SO can be reduced back to 
Met by MrsA and MsrB, respectively [27]. These enzymes have been reported to play 
important roles in the protection of cells and proteins against oxidative stress [14, 34, 67-
71]. Reversible Met oxidation has also been proposed to scavenge ROS thereby 
protecting cells from oxidative damage [17, 44, 72]. Increased expression of MsrA and 
MsrB can extend the lifespan of yeast cells and fruit flies, whereas deletion of the MsrA 
gene leads to the reduction in lifespan in mice and yeast [46, 73, 74]. 
Previously, three MsrB isozymes and a single MsrA were found in mammals. 
MsrB1 (also known as SelR or SelX) is a selenoprotein, which contains Sec in the active 
site and is localized to cytosol and nucleus. MsrB2 and MsrB3 are Cys-containing 
homologs of MsrB1. MsrB2 resides in mitochondria, whereas human MsrB3 has two 
alternative splice forms, wherein MsrB3A localizes to the ER and MsrB3B is targeted to 
mitochondria [35]. 
The catalytic mechanism of MsrA involves a sulfenic acid intermediate at the 
catalytic Cys followed by the formation of a disulfide bond between the catalytic and 
resolving Cys. A third Cys may then form a disulfide with the resolving Cys [49, 75]. 
The resulting disulfide is reduced by thioredoxin or other oxidoreductases, generating the 
initial, reduced form of the protein. X-ray structures of MsrAs from several organisms 
have been solved [49, 76].  
Cys-containing MsrBs (e.g., mammalian MsrB2 and MsrB3) follow the same 
mechanism, even though the two Msr types have no homology and are characterized by 
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different structural folds [23, 50, 77]. Sec-containing mammalian MsrB1 has also been 
characterized and compared to Cys-containing MsrBs [50]. Interestingly, Cys-containing 
MsrBs share some active-site features (e.g., conserved residues His77, Val81 and Asn97, 
numbering based on mouse MsrB1 sequence) which are absent in selenoprotein MsrB1s. 
When these three residues were introduced into the Sec-containing MsrB1, the enzyme 
was inactive. However, when the three residues were introduced into the Cys mutant 
form of MsrB1, the activity was partially recovered [50]. This evidence supports the idea 
that catalytic Cys and Sec require different active site features.  
In addition to MsrA and MsrB functions, previous studies suggested the presence 
of additional Msr activities in E. coli and yeast cells, which were especially evident in 
cells deficient in both enzymes [23, 32, 74, 78]. Recently, Lowther and colleagues 
discovered a new enzyme, designated fRMsr, which catalyzes the reduction of free Met-
R-SO in E. coli [37]. They showed that this activity is associated with a GAF-like-
domain-containing protein. Homologs of this enzyme were found in other bacteria as 
well as in eukaryotes, suggesting that these proteins also could function as fRMsrs. 
However, none of these other proteins have been functionally characterized.  
In this work, we cloned a yeast homolog of bacterial fRMsr and functionally 
characterized it with regard to the in vivo function and catalytic mechanism. In addition, 
we carried out comparative genomic analyses to examine evolution of this protein family. 
The data show that fRMsr is the main enzyme responsible for the reduction of free Met-
R-SO in both prokaryotes and unicellular eukaryotes. 
 
2.3. Experimental procedures 
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Materials. E. coli NovaBlue cells (Novagen) were used for DNA manipulation 
and BL21 (DE3) cells (Invitrogen) for protein expression. Restriction enzymes were from 
Fermentas, PCR reagents from Invitrogen, and Talon polyhistidine affinity resin from 
Clontech.  
Comparative genomic analyses of fRMsrs in prokaryotes and eukaryotes. 
Sequenced genomes of archaea, bacteria and eukaryotes were retrieved from the NCBI 
website (http://www.ncbi.nlm.nih.gov/sutils/genom_table.cgi). A total of 540 bacterial, 
48 archaeal and 160 eukaryotic organisms were analyzed (as of March 2008). We used E. 
coli (NP_416346) and S. cerevisiae fRMsr proteins (NP_012854) as our seed sequences 
to search for homologs in other organisms. TBLASTN [79] was used with default 
parameters. Orthologous proteins were defined as bidirectional best hits [80].  
Multiple sequence alignment and phylogenetic analysis. A phylogenetic tree 
based on concatenation of 31 orthologs occurring in 191 species [81] was used to analyze 
the distribution of organisms that do or do not contain fRMsrs. Multiple sequence 
alignments were performed using CLUSTALW [82] with default parameters and 
ambiguous alignments in highly variable regions excluded. Phylogenetic trees were 
reconstructed with PHYLIP programs [83]. Neighbor-joining (NJ) trees were obtained 
with NEIGHBOR and the most parsimonious trees were determined with PROTPARS. 
The robustness of these trees was evaluated by maximum likelihood (ML) analysis with 
PHYML [84] and Bayesian estimation of phylogeny with MrBayes [85]. 
Computational analysis of the active site of yeast fRMsr. In silico analysis of 
the active site was carried out using the structure of oxidized yeast fRMsr with PDB code 
1F5M. The structure was adjusted with the program VegaZZ 2.2.0 
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(http://www.vegazz.net/) to reduce the disulfide bond and protonate residues, and 
minimized (60 steps of 0.05 Å, steepest descent global minimization) with UCSF 
Chimera (http://www.cgl.ucsf.edu/chimera/). The active site was analyzed with Q-site 
finder (http://bmbpcu36.leeds.ac.uk/qsitefinder/), which assesses residue accessibility to a 
small molecular probe and then ranks up to ten potential active sites [86]. The top-ranked 
predicted active sites were considered as the most probable sites of catalysis. The 
theoretical titration data for each putative catalytic Cys were obtained using the H++ 
server (http://biophysics.cs.vt.edu/H++/index.php, [89]), which calculates theoretical pKa 
values and estimates variation of the charge state on the titrable atom of each titrable 
residue at different pH values. These values were then superimposed with the calculated 
curves for a typical HH behavior at the corresponding theoretical pKa. The assumptions 
were that deviating titrable residues more frequently occur in enzyme active sites [87, 88, 
90] and that the theoretical titration curves may indicate the tendency of the residue to be 
catalytic. Finally, visual inspections of the titration curves were carried out for curves 
with the largest deviation from the standard HH behavior as candidate residues of the 
active site [87, 90]. 
Computational docking of Met-R-SO into fRMsr active site and molecular 
dynamics. The structure of yeast fRMsr (1F5M) was prepared for docking using VegaZZ 
2.2.0, ArgusLab 4.0 (http://www.arguslab.com/) and the Autodock 
(http://autodock.scripps.edu/) suite of programs. VegaZZ was also employed to prepare 
the Met-R-SO substrate (downloaded from the ZINC database). The SP4 force field and 
the AMMP-mom method were employed to assign charges to Met-R-SO and to minimize 
the structure. The substrate was then exported to ArgusLab. The yeast fRMsr structure 
15 
 
was virtually reduced with VegaZZ building tools. The structure for the reduced protein 
was treated with Tinker (http://dasher.wustl.edu/tinker/) for extensive minimization 
dynamics. Using the AMBER99 force field and gradient convergence per atom criterion 
of 0.01 kcal/mol/Å, the reduced structure employed in the docking calculation was 
obtained. Molecular dynamics experiments were done with Tinker, using the dynamics 
option. We conducted first non boundary dynamics starting from the reduced, but not 
minimized, structure. We sampled time steps in the range 0.01-1.0 fs and overall 
dynamics time up to 200 ps, and performed calculations at 300 K and 1 atmosphere. 
After evaluation of the time range (0-1 ps), in which the clear movement of the active site 
Cys was detectable, we carried out final calculations with the following parameters: time 
step = 0.1 fs, number of steps = 1,000,000 and the dumps time = 0.05 ps. Analysis of 
trajectories was done with Tinker, VegaZZ; the root mean square fluctuation (standard 
definition) of carbon alpha was calculated starting from the structures of our ensemble 
with in–house programs. For docking, the substrate was analyzed in the intercalation site 
using a docking box of 20x20x20 Å centered at the approximate center of mass of the 
two candidate catalytic Cys residues (Cys101 and Cys125). We employed the GAdock 
docking engine, a genetic algorithm search technique implemented in ArgusLab. To set 
up the docking parameters, calculations were made with the following values: population 
size 250, max generations 100,000, mutation rate 0.02, grid resolution 0.1 Å, flexible 
ligand mode (other parameters were kept with default values). Docking calculations with 
AutoDock 4 were run in Linux environment making use of the ADT graphical user 
interface (http://mgltools.scripps.edu/). We imported the same Met-R-SO and yeast 
fRMsr structures employed for ArgusLab dockings. While with ArgusLab, the protein 
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structure was forced to be rigid during the docking, with AutoDock it was possible to 
define a subset of flexible amino acids which were free to move during the docking. We 
defined as flexible the following residues: Tyr70, Leu80, Val89, Ala90, Cys91, Ile94, 
Gly99, Val100, Cys101, Gly102, Thr103, Ala104, Ala105, Ile123, Ala124, Cys125, and 
Asp126. These residues can be considered as an extended reaction center around the three 
Cys (91, 101, and 125). Again, the docking box 20x20x20 Å was centered around the 
approximate center of mass of the two candidate catalytic Cys residues (Cys101 and 
Cys125). We employed the genetic algorithm search with the following parameters: 
population size 250, max generations 50,000, mutation rate 0.02, maximum number of 
energy evaluation 10000000, grid resolution 0.2 Å, flexible ligand mode. Images were 
prepared with UCSF Chimera, VegaZZ and PyMol (http://pymol.sourceforge.net/) 
packages. 
Preparation and verification of Msr mutant strains. The yeast strains used in 
this study were derivatives of wild type BY4741 cells. Mutants missing two or three Msr 
genes were generated by a one-step gene disruption method using markers described in 
Table S1 [94]. The HIS3 marker was amplified from p423 vector with the following 
primers: 5’- 
CGGTTTCTTCATGTTTATATGATGACGATTTTCCCAAATGTAAGCAAACAAAG
GCGACTGCCAGGTATCGTTTGAACACG-3’, and 5’-
TGCCCGTCCGACAATATATTTGACAAGAGAGCTACATGGGAATATTGGTTAT
GTCGTATGCTGCAGCTTTAAATAATCGG-3’. PCR products were purified from 
agarose gel and used for yeast transformation. Mutant clones were selected in minimal 
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histidine-free medium. Deletions of each ORF were confirmed by PCR. Yeast strains 
used in this study are listed in Table S1. 
Cloning, expression and purification of yeast fRMsr. The gene coding for 
fRMsr was amplified from yeast genomic DNA with the following primers (restriction 
enzyme sites NdeI and NotI are in bold and underlined): fRMrs-F 5’- 
AAACATATGATGGGCTCATCAACCGGGTTTC-3’, and fRMrs-R 5’-  
AAGCGGCCGCGACACATGATTTATTAATTAATTTAGCAAG-3’. The PCR 
product was digested with NdeI and NotI and cloned into pET21b vector (Novagen) and 
then transformed into E. coli NovaBlue cells. The constructs were verified by restriction 
enzyme digestion and direct sequencing. The plasmid harboring the correct insert was 
transformed into E. coli BL21 (DE3) cells for protein expression. These cells were grown 
in LB medium containing 100 µg/ml ampicillin until OD600 reached 0.8, and IPTG was 
added to a final concentration of 0.25 mM. Induction of protein synthesis proceeded at 30 
°C for 4 h, and cells were then harvested by centrifugation at 4,000 rpm. Cell pellets were 
washed with PBS and recentrifuged. Harvested cells were stored at -70 °C until use. 
To purify recombinant protein, cell pellets were mixed with resuspension buffer 
(50 mM Tris-HCl, pH 7.5, 15 mM imidazole, 300 mM NaCl), and PMSF was added to a 
final concentration of 0.5 mM. After sonication, the supernatant was collected by 
centrifugation at 8,000 rpm for 30 min and loaded on a cobalt Talon resin (Clontech, CA, 
USA) pre-equilibrated with resuspension buffer. Following washing with the same 
buffer, the protein was eluted with elution buffer (50 mM Tris-HCl, pH 7.5, 300 mM 
imidazole, 300 mM NaCl). The eluted fractions were analyzed by SDS-PAGE, and the 
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fractions containing fRMsr were pooled and dialyzed overnight against PBS in a dialysis 
cassette (Pierce). 
Site-directed mutagenesis of fRMsr. Substitutions of Cys with Ser at positions 
91, 101 and 125 were carried out using QuickChange protocol (Stratagene) with the 
following primers: C91Sf: 5’-GGAAAGGTCGCTAGCCAAATGATTC-3’; C91Sr: 5’- 
GAATCATTTGGCTAGCGACCTTTCC-3’; 
C101Sf: 5’-GGTAAAGGTGTTAGCGGAACTGCAGC-3’; C101Sr: 5’- 
GCTGCAGTTCCGCTAACACCTTTACC-3’; C125Sf: 5’- 
GTCATATTGCGAGCGACGGTGAAAC-3’; and C125Sr: 5’- 
GTTTCACCGTCGCTCGCAATATGAC -3’. After PCR reactions, wild-type template 
was digested with DpnI, column-purified, and the PCR products were transformed into E. 
coli NovaBlue cells. Mutations were confirmed by DNA sequencing. Plasmids carrying 
correct mutations were transformed into E. coli BL21(DE3) and protein expression was 
carried out as described above. 
Determination of fRMsr activity. The reaction mixture (20 µl in PBS pH 7.4) 
included 50 mM DTT, 1 mM substrate (Met-R-SO or Met-S-SO), and the reaction was 
initiated by the addition of purified enzyme. The reaction proceeded at 37 °C for 30 min 
and then was stopped by adding 2 µl of TCA. After further incubation at 4 °C for 10 min 
and centrifugation at 13,000 rpm for 15 min, the supernatant (5 µl) was mixed with the 
OPA derivatization reagent to a 100 l final volume as described [34]. Following a 2 min 
reaction at room temperature, 50 l of the mixture were injected onto a Zorbax Eclipse 
XDB-C8 column (4.6×150 mm) initially equilibrated at room temperature with 20 mM 
sodium acetate, pH 5.8 (solvent A) and methanol (solvent B) at a ratio of 88:12 (v/v). 
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Met was separated at room temperature at a flow rate of 1.5 ml/min using a linear 
gradient of 12-40% methanol from 0 to 5 min, 40-47% methanol from 5 to 40 min, and 
47-100% methanol from 40 to 45 min. Detection was by fluorescence of Met derivatives 
using a Waters 474 scanning fluorescence detector with excitation at 330 nm and 
emission at 445 nm. 
The reduction of free Met-R-SO was also determined by a coupled assay. Briefly, 
a 100 µl reaction mixture contained 5 µg of purified fRMsr, 5 µg E. coli thioredoxin 
(Trx), 0.5 µl E. coli thioredoxin reductase (Sigma), 0.4 mM NADPH and free Met-R-SO. 
The reaction was allowed to take place at 37 °C for 15 min, 200 µl of PBS was added to 
the reaction mixture, and NADPH oxidation was analyzed immediately at OD340. The 
activity was calculated using NADPH extinction coefficient (6220 M-1cm-1). 
Viability assays and oxidative stress resistance. Yeast strains were grown in 
liquid media overnight and then seeded into fresh liquid medium at the OD600 of 0.1. The 
cultures were allowed to reach OD600 of 0.4-0.5, diluted to OD600 of 0.1-0.2 and used for 
viability assays. Briefly, 50 µl yeast culture was inoculated into 1 ml of liquid medium, 
and of that, 50 µl was diluted into 450 µl of medium and used to count colonies at time 
zero. H2O2 was then added, at indicated concentrations, to 1 ml cultures, and the cells 
were further incubated at 30 °C. At 30, 60, and 120 min after treatment, 50 µl of each 
culture was diluted into 450 µl of liquid medium. To count viable colonies, the diluted 
cultures were mixed with 3 ml of liquid medium supplemented with 0.4% agarose held in 
a water bath at 42 oC, and the resulting mixtures were poured onto agar plates containing 
the same medium components as the liquid medium. Viability of wild-type and deletion 
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mutant strains was assayed in YPD or YNB media, and those of wild-type strains 
overexpressing vector or yeast fRMsr were assayed in YNB medium without histidine. 
For plate assays, overnight cultures of wild-type and deletion mutant strains were 
adjusted to an OD600 of 2.5, 0.25, 0.025, and 0.0025 via serial dilution. Each diluted 
sample (5 µl) was spotted onto YNB agar medium in the presence or absence of indicated 
concentrations of H2O2 and cell growth was quantified after incubation for 3 days at 
30°C. 
Analysis of microarray data. Data on expression levels of fRMsr 
(GDS777/10627_at/YKL069W), MsrA (GDS777/5697_at/MXR1), and MsrB 
(GDS777/6899_at/YCL033C) at different nutrient-limiting conditions (i.e., carbon, 
nitrogen, phosphorus, and sulfur) and at different oxygen availability (i.e., aerobic and 
anaerobic)) were collected from GEO profiles [96]. Data from three single channels were 
averaged, and standard deviations were calculated.  
Preparation of human thioredoxin 1 (hTrx1) Cys35Ser mutant-immobilized 
resins and Cys targeting. Cys35Ser hTrx1-immobilized resins were prepared to trap 
resolving cysteines of fRMsr. Briefly, mutant Cys35Ser hTrx1 in 0.1 M sodium carbonate 
buffer (pH 8.5) containing 0.5 M NaCl was incubated with cyanogen bromide-activated 
Sepharose 4B (Sigma) that had been swelled according to the manufacturer's instructions. 
The coupling reaction was stopped by centrifugation, and unreacted side chains on the 
resin were blocked with 0.2 M glycine (pH 8.0) for 2 h at room temperature. After 
extensive washing with the basic coupling buffer described above and acetate buffer (0.1 
M, pH 4) several times, immobilized Cys35Ser hTrx1 was quantified based on the 
difference between the amounts of protein initially used and remaining in solution after 
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the coupling reaction. To search for residues targeted by Cys35Ser hTrx1, various fRMsr 
forms (wild-type, Cys91Ser, Cys101Ser, Cys125Ser, or Cys101/125Ser; 50 µg of each) 
were incubated with 0.5 ml of Cys35Ser hTrx1-immobilized resin at room temperature 
for 2 h under gentle stirring. Immobilized Cys35Ser hTrx1 was initially reduced with 1 
mM DTT for 30 min and washed with 50 mM sodium phosphate buffer (pH 7.5, 50 mM 
NaCl). After incubating the Cys35Ser hTrx1-immobilized resin with each fRMsr form at 
room temperature for 2 h, the resins were suspended in 50 mM sodium phosphate buffer 
(pH 7.5, 50 mM NaCl, 10 mM DTT) and incubated at room temperature for 30 min. 
During the whole process, initial samples prior to incubation with the Cys35Ser hTrx1-
immobilized resin (I), flow through samples after incubation with the resin (F), and 
elution samples after 10 mM DTT treatment (E) were collected and 10 µl of each fraction 
were loaded on SDS-polyacrylamide gels and visualized by Western blot with anti-fRMsr 
antibodies. 
 
2.4. Results 
Comparative genomics of fRMsrs. Analysis of completely sequenced genomes 
revealed a restricted (compared to MsrA and MsrB) use of fRMsr (a list of analyzed 
organisms is shown in Table 2.1.). 41.5% of all examined bacteria, 6% archaea and 
44.4% eukaryotes were found to possess this protein, and each of these organisms 
contained a single copy of fRMsr. The distribution of fRMsrs was further analyzed in 
detail in bacteria (Fig. 2.1.), archaea (Fig. 2.2.), and eukaryotes (Fig. 2.3.) based on a 
highly resolved tree of life [81] (see supporting information). Interestingly, the 
occurrence of this protein was limited to unicellular organisms, whereas higher plants and 
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animals lacked this protein. Two variants (or subtypes) of fRMsr proteins were detected. 
Both contained two fully conserved Cys residues (i.e., Cys101 and Cys125 in S. 
cerevisiae fRMsr) which were absent in other GAF-domain-containing proteins. Thus, 
these two residues represent a signature for the identification of fRMsr sequences. Type I 
fRMsrs possessed an additional conserved Cys (e.g., Cys91 in S. cerevisiae fRMsr) 
which was invariantly absent in type II fRMsrs. Occurrence of the two fRMsrs types is 
shown in Fig. 2.1.-2.3., and multiple alignment of fRMsr sequences in Fig. 2.4. No 
organism possessing both fRMsr types was detected. Type II fRMsrs had lower 
occurrence and were found in 26 bacteria, 3 archaea and 2 eukaryotes characterized by 
complete genome sequences. Phylogenetic analysis was used to further examine the 
evolutionary relationships of the two types of fRMsrs in different organisms (Fig. 2.5.).  
We also examined domain fusions involving fRMsr in eukaryotes and prokaryotes 
(Fig. 2.6.). One example involved type I fRMsr that was fused with a homolog of TIP41 
(pfam04176, TIP41-like family) [37] in Kinetoplastida (including Leishmania and 
Trypanosoma, Fig. 2.6.A). TIP41 was reported to be involved in the regulation of yeast 
type 2A phosphatases [97]. However, the functional relationship between TIP41 and 
fRMsr is not clear. Similarly, in bacteria, all type II fRMsrs in sequenced Thermotogaes 
contained an unknown N-terminal domain (designated Unknown_1, Fig. 2.6.B). In 
Fervidobacterium nodosum, which belongs to Thermotogae, an additional GGDEF 
domain (pfam00990, GGDEF domain) was found to be fused at the C-terminus of fRMsr 
(Fig. 2.6.C). Overall, functional genomics analysis of fRMsr homologs revealed the 
presence of these proteins in all three domains of life. 
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Table 2.1. Yeast strains used in this study 
 
Strain Description Genotype Source 
BY4741 WT MATa his3 leu2 met15 ura3 SGDP* 
GY2 ∆MsrB 
MATa his3 leu2 met15 ura3, 
∆msrB:KAN 
SGDP* 
GY4 ∆MsrA 
MATa his3 leu2 met15 ura3, 
∆msrA:KAN 
SGDP* 
GY3 ∆fRMsr 
MATa his3 leu2 met15 ura3, 
∆fRMsr:KAN 
SGDP* 
GY5 ∆MsrA∆ MsrB 
MATa his3 leu2 met15 ura3, 
∆msrB:KAN ∆msrA:ura3 
[14] in the 
main text 
GY200 ∆MsrA ∆fRMsr 
MATa his3 leu2 met15 ura3, 
∆msrA:KAN ∆fRMsr:his3 
This work 
GY201 ∆MsrB∆ fRMsr 
MATa his3 leu2 met15 ura3, 
∆msrB:KAN ∆fRMsr:his3 
This work 
GY202 
∆MsrA∆ MsrB∆ 
fRMsr 
MATa his3 leu2 met15 ura3, 
∆msrB:KAN ∆msrA:ura3 
∆fRMsr:his3 
This work 
 
SGDP - Saccharomyces Genome Deletion Project (http://www-
sequence.stanford.edu/group/yeast_deletion_project/deletions3.html) 
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Fig. 2.1. Occurrence of fRMsr proteins in bacteria. The tree is based on the bacterial 
segment of a highly resolved phylogenetic tree of life. Occurrence of type I (containing 3 
conserved Cys residues) and type II (containing 2 conserved Cys residues) fRMsrs is 
shown separately. 
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Fig. 2.2. Occurrence of fRMsr proteins in archaea. All three fRMsr-containing 
organisms possess type II fRMsr. 
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Fig. 2.3. Occurrence of fRMsr proteins in eukaryotes. Occurrence of type I and type II 
fRMsrs is shown separately. 
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Fig. 2.4. Multiple sequence alignment of fRMsr proteins. The alignment shows 
regions containing the three conserved Cys in both types of fRMsr. Conserved residues 
are highlighted. The predicted functional Cys (C) residues are shown with asterisks. 
Distant fRMsr homologs, GAF-domain proteins, are shown for comparison. 
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Fig. 2.5. Phylogenetic tree of fRMsrs in prokaryotes and eukaryotes. 100 
representative sequences were selected from a larger set of homologs. Non-fRMsr GAF-
containing protein branches were compressed and are represented by family names. The 
measurement of distance for the branch lengths (shown by a bar) is indicated. 
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Fig. 2.6. Domain fusions involving fRMsr proteins. (A) fRMsr fused with TIP41-like 
domain (pfam04176) in Kinetoplastida. (B) fRMsr fused with an unknown domain 
Unknown_1 in Thermotogae; (C) fRMsr fused with both Unknown_1 and GGDEF 
domain (pfam00990) in Fervidobacterium nodosum. 
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fRMsr showed lower occurrence than MsrA or MsrB and also was present in single 
copies in organisms containing this protein. Our data suggested that all fRMsr sequences 
may have a similar function: by analogy to the E. coli fRMsr, which naturally reduces 
free Met-R-SO, other organisms also could use fRMsr for this function.  
fRMsr is important for Met-R-SO consumption and growth of yeast cells on 
Met-R-SO. For functional characterization, we chose a S. cerevisiae fRMsr homolog 
(YKL069W) which is annotated as a putative protein of unknown function. We prepared 
mutant cells deficient in fRMsr and its double mutants with MsrA or MsrB. We first 
examined the growth of these and wild-type cells on YNB agar media in which Met was 
substituted with Met-R-SO or Met-S-SO. Fig. 2.7.A shows that the deficiency in fRMsr, 
MsrA or MsrB only slightly decreased the growth of yeast cells on Met-R-SO. The 
growth was reduced more significantly, when both MsrA and MsrB were deleted [36]. 
Interestingly, deletion of fRMsr and MsrA completely blocked the growth of yeast cells, 
suggesting that these two proteins were responsible for the reduction of Met sulfoxides in 
S. cerevisiae. In this regard, the growth of the fRMsr mutant strain on Met-R-SO may be 
explained by the presence of small amounts of Met-S-SO in the Met-R-SO preparation or 
by the lower requirement for Met in this assay.  
In the media where Met was replaced with Met-S-SO (Fig. 2.7.B), deletion of 
fRMsr or MsrB had no effect on the growth of yeast cells; however, deletion of MsrA 
reduced the growth significantly. The combined MsrA and fRMsr deletion further reduced 
the growth of yeast cells. Again, a small contribution of fRMsr to the growth of MsrA-
deficient cells on Met-S-SO may be explained by trace amounts of Met-R-SO present in  
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Fig. 2.7. Roles of Msrs in utilization of Met-SO by S. cerevisiae cells. Yeast strains 
were analyzed for growth on Met-free YNB medium supplemented with 20 mg/l Met-R-
SO (A), Met-S-SO (B) or Met (C). Cells were initially grown on YNB liquid medium 
until OD600 reached 0.6, harvested, washed, diluted to OD600 of 0.1 in water and serially 
spotted on agar YNB plates containing respective Met or Met-SO sources. The plates 
were incubated at 30 °C and pictures were taken after 48 h. Designation of yeast strains is 
as follows: ∆A, cells with MsrA gene deleted: ∆B, cells missing the MsrB gene: ∆F, cells 
with deletion of fRMsr gene. Cells missing liquid culture assay. To further examine Met-
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SO reduction in S. cerevisiae, we prepared and characterized a mutant strain lacking all 
three enzymes (i.e., MsrA, MsrB and fRMsr). The triple mutant multiple Msrs were also 
analyzed as shown as well as mutant cells containing a vector (+v) or expressing fRMsr 
(+pF). (D) Growth of wild-type and mutant strains of S. cerevisiae in liquid media (Met-
free YNB supplemented with 20 mg/l Met-R-SO). The growth of yeast cells was 
monitored by measuring OD600. Designations of WT and mutant cells as in panels A-C. 
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the Met-S-SO preparation. None of the mutant strains showed significant growth defects 
in Met media (Fig. 2.7.C). The results of the assay in liquid medium containing Met-R-
SO instead of Met are shown in Fig. 2.7.D. The complete growth inhibition of the fRMsr 
mutant in Met-R-SO medium was observed in this overexpressing fRMsr was shown to 
restore the growth. These data clearly demonstrate the role of fRMsr in the reduction of 
free Met-R-SO. Overall, the data shows that fRMsr is the main enzyme responsible for 
Met-R-SO reduction in yeast and likely other organisms, and MsrA is the main enzyme 
reducing free Met-S-SO.  
Yeast fRMsr serves as an antioxidant protein. Wild-type and fRMsr mutant 
strains, as well as cells transformed with control vector or the vector expressing fRMsr 
were tested for sensitivity to oxidative stress. Strains deleted for MsrB gene or 
overexpressing this protein were included for comparison. As shown in Fig. 2.8.A, in the 
presence of 1 mM H2O2, deletion of the fRMsr gene resulted in reduced viability at 30 
min. Fig. 2.8.B shows that, in the presence of 1 mM H2O2, the yeast cells overexpressing 
fRMsr showed an increased resistance to peroxide treatment (compared to control cells). 
The antioxidant role of fRMsr was further confirmed in plate assays (Fig. 2.8.C). The 
fRMsr mutant was more sensitive to H2O2-mediated cell death compared to wild-type 
cells. However, the deletion of fRMsr less affected sensitivity to oxidative stress than that 
of MsrA or MsrB. Thus, fRMsr as well as MsrA and MsrB serve as antioxidants in yeast 
cells.  
A recent study examined global gene expression in yeast cells under the limitation 
of nutrients, such as carbon, nitrogen, phosphorus and sulfur, as well as examined the 
effect of oxygen availability [96]. Expression data for fRMsr, MsrA, MsrB were retrieved  
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Fig. 2.8. Sensitivity of wild-type and mutant strains to oxidative stress. Indicated 
strains of S. cerevisiae were grown in liquid media containing 1 mM H2O2 and after the 
indicated periods of time the viability was assayed as described in Experimental 
Procedures. (A) Remaining viable fraction of WT and mutant strains in YPD media. (B) 
Remaining viable fraction of WT cells expressing fRMsr or a vector (control). (C) Plate 
assay. Wild-type and mutant yeast cells were incubated on YNB agar medium, treated or 
not with 1.2 mM or 1.5 mM H2O2, and the pictures were taken after 3 days at 30 °C. 
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Fig. 2.9. Changes in expression levels of three Msr genes under the limitation of 
different nutrients and oxygen availability. (A) fRMsr, (B) MsrA, (C) MsrB. The data 
were retrieved from GEO profiles. C, carbon; N, nitrogen; P, phosphorus; S, sulfur. 
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from GEO Profiles and are shown in Fig. 2.9. Under aerobic conditions, fRMsr gene 
expression was elevated when sulfur was limiting in the growth medium. MsrA was also 
elevated, but MsrB was not. However, under anaerobic conditions, neither fRMsr nor 
MsrA gene expression was affected when sulfur was limiting in the medium. These data 
suggest that, in the presence of oxygen (when ROS levels are higher), MsrA and fRMsr 
(but not MsrB) likely contribute to sulfur acquisition by reducing Met-S-SO and Met-R-
SO, respectively.  
Roles of yeast fRMsr in aging. Wild-type and mutant strains deficient in 
individual Msrs and their combinations were analyzed for lifespan in a replicative assay 
of yeast aging. Deletion of MsrB did not influence lifespan, whereas fRMsr and MsrA 
mutant strains showed a reduced lifespan (18% and 30%, respectively) (Fig. 2.10.A). To 
further elucidate the role of fRMsr in aging, the lifespans of ∆fRMsr∆MsrA, 
∆fRMsr∆MsrB and ∆fRMsr∆MsrA∆MsrB cells were determined. These strains showed 
20% reduction in lifespan compared to wild-type cells, which was not significantly 
different from the lifespan of cells lacking only fRMsr. fRMsr overexpression did not 
extend yeast lifespan in cells grown in minimal YNB media (Fig. 2.10.B).  
Characterization of catalytic properties of fRMsr. To explore enzymatic 
properties of yeast fRMsr, we expressed this protein in E. coli as a His-tagged protein and 
examined its catalytic properties. The recombinant protein had robust Met-R-SO 
reductase activity, but was inactive with Met-S-SO as well as dabsylated Met-R-SO. 
Kinetic parameters derived by fitting the experimental data onto Michaelis-Menten  
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Fig. 2.10. Lifespan analysis of yeast cells deficient in Msrs or overexpressing fRMsr. 
Replicative assays were used to determine lifespan of indicated mutant and WT yeast 
cells by counting the number of daughter cells produced by mother cells. Designation of 
yeast strains is as follows: (A) ∆A, MsrA mutant: ∆B, MsrB mutant: ∆F, fRMsr mutant. 
Cells lacking fRMsr and MsrA or MsrB, as well as cells with deletion of all three Msrs 
were analyzed in YPD media. (B) Lifespan of cells overexpressing fRMsr and control 
cells containing an empty vector was analyzed in minimal medium.  
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Fig. 2.11. Substrate saturation curve of fRMsr. Vmax and Km values for free Met-R-SO 
were determined by fitting experimental data, which were obtained by a coupled assay, 
on the Michaelis-Menten equation. 
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equation are shown in Fig. 2.11. The enzyme had a Vmax value of 443 nmol/min/mg 
protein and its Km value for free Met-R-SO was 230 µM. 
Identification of catalytic Cys in fRMsr. We searched for catalytic Cys in S. 
cerevisiae fRMsr by analyzing properties of the active site in this protein. The Q-site 
finder prediction placed three Cys residues (Cys91, Cys101 and Cys125) in the most 
probable enzymatic cleft for fRMsr. The same three Cys residues were also identified in 
E. coli fRMsr [37]. However, while Cys101 and Cys125 provided their sulfur atoms for 
possible substrate binding, only the backbone atoms of Cys91 were involved. The best-
scoring predicted active site was composed of Trp66, Tyr70, Ala90, Ile94, Glu99, 
Val100, Cys101, Val116, His112, Ile122, Ala124, Cys125, Asp126, Thr129, Glu132, 
Asp149, and Asp151 (Fig. 2.12.). 
We further analyzed the theoretical titration behavior for Cys91, Cys101, and 
Cys125 using the H++ server to fit into the standard HH curve (Fig. 2.13.). The deviating 
fitting was more pronounced for Cys125 and Cys101, but Cys91 showed a non-deviating 
curve similar to most residues in proteins [89] including Cys177 in fRMsr. On the 
assumption that highly deviating titrable residues are often located in enzyme active sites 
[87, 88, 90], these results suggested Cys125 or Cys101, but not Cys91, as the residues 
directly involved in reducing free Met-R-SO. Cys125 was in a close proximity to two 
other titrable residues showing HH deviating behavior, Tyr70 and Asp151, while Cys101 
clustered with highly deviating Glu132 and Asp149. Altogether, computational analyses 
suggested that Cys125 and Cys101 were candidate catalytic residues, while Cys 91 was 
not. 
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Fig. 2.12. Consensus cluster of Met-R-SO models docked into yeast fRMsr. The 
cluster in the Figure refers to 5 models obtained as described in Experimental Procedures.  
This cluster is includes the most favorable models (i.e., interaction energy value, - 8.1 
kcal/mol, short S-S distance, 2.4 Å) we found in all our calculations (see Figure 8 in the 
main text). Cys101 (right part of the figure) and Cys125 (left) are shown in sticks, and the 
substrate Met-R-SO is represented in balls and sticks, while other nearby residues are 
shown in wireframe.  
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Fig. 2.13. Theoretical titration curves of Cys residues in yeast fRMsr. Theoretical 
titration curves (shown in red), calculated via the H++ server, were superimposed with 
the corresponding standard Henderson-Hasselbach (HH) behaving titration curves 
(shown in blue). The y-axis refers to the calculated charge on the Cys sulfur atom. The 
deviation from a typical HH behavior is considered to be an important feature of active 
site residues. Most residues in proteins have HH-like titration curves, like those of Cys91 
and Cys177 in the figure. Cys125 is the most perturbed Cys residue in yeast fRMsr. As 
can be seen, the H++ calculated pKa of both Cys 125 and Cys 101 are high. However, 
this property is not as relevant as the deviation from the HH behavior in analysis of active 
sites under the THEMATICS assumptions. 
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To further analyze Cys residues participating in catalysis and to characterize the 
reaction mechanism of fRMsr, we carried out computational docking of Met-R-SO into 
the active site of the enzyme as described in Experimental Procedures. Employing 
different methodologies, we consistently observed the same Met-R-SO-binding site in 
yeast fRMsr (shown as cluster of scoring models in Fig. 2.12.). Among these models, the 
best scoring candidate (interaction energy of -8.1 kcal/mol) is shown in Fig. 2.14. This 
binding structure was detected by both AutoDock and ArguLab, with the substrate close 
to both Cys101 and Cys125 and pointing the sulfoxide moiety toward the sulfur atom of 
Cys101 (at a distance of 2.4 Å). Cys125 appeared to orient the substrate to react with 
Cys101. Given that this model was reproduced with different docking methods, and 
received good scores, our data suggested that Cys101 is the catalytic residue, and Cys125 
the initial resolving Cys. In addition, we observed that Cys125 was remarkably more 
mobile than either Cys91 or Cys101 (the latter is least mobile of the three) (Fig. 2.15.). 
Following reduction of the disulfide bond, Cys125 moves away from Cys91 (from 2.1 Å 
to 6.9 Å), coming closer to Cys101 and Asp151 (from 7.1 Å to 4.6 Å).  
Our reduced structure model (i.e., the most stable reduced form of the protein) 
presents a Cys125-Asp151 distance of 3.6 Å, taken as the shortest atomic distance 
between the two residues (Fig. 2.15.), which is very similar to the previously observed 
distance (3.5 Å) of the reduced form of yeast fRMsr [38]. In this work, it was found that 
Cys125 occurs in two different conformations when in oxidized and reduced forms, the 
latter positioned near Asp151 and away from Cys91. Thus, our data are consistent with 
the previous structural analysis [38] and further suggested that Cys125 is the most mobile 
Cys in the active site.  
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Fig. 2.14. Active site of yeast fRMsr. Met-R-SO was docked into the active site as 
described in Experimental Procedures. This figure was created with UCSF Chimera 
package. Cys91 and Cys125 are shown in stick representation; Cys101 and Met-R-SO 
(also highlighted with green contour) are shown in ball and stick representation. The rest 
of the protein is shown in ribbon. The model shows that that the substrate is oriented by 
both Cys101 and Cys125; at the same time the reactive sulfoxide group points toward 
Cys101 sulfur atom (at a distance of 2.4 A), which is a predicted catalytic Cys.  
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Figure 2.15. Mobility of Cys91, Cys125 and Cys101 residues following reduction of 
the disulfide between Cys125 and Cys91. The initial position (oxidized fRMsr, PDB 
1F5M) is shown in grey stick representation, while green sticks show the residues after 
minimization. An early intermediate structure (after the first 60 steps of minimization) 
during the MD minimization trajectory is also shown in grey sticks. Cys125 moves much 
more extensively than the other two Cys (moving away from Cys91 and closer to 
Cys101) supporting its role as the resolving Cys. Cys101 is least mobile among the three 
Cys, supporting its role as the catalytic residue. In our reduced and minimized model, the 
Cys125-Asp151 distance is 3.6 Å (6.6 Å in the oxidized form). 
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We carried out molecular dynamics calculations to further address Cys125 
mobility in a short time scale (0 to 200 ps). The movement of Cys125 was very quick 
(within 1 ps, Fig. 2.16.). At the same time, other Cys were stationary preserving their 
initial positions. Following the initial movement, Cys125 mobility was not significantly 
different compared to the other active site residues (i.e., its fluctuations were comparable 
to those of Cys91 and Cys101). Thus, Cys125 is initially the most mobile active site Cys, 
in agreement with the expected properties of the resolving Cys.  
Catalytic activity of fRMsr mutants and Cys targeting by hTrx1. To directly 
determine the roles of Cys residues in fRMsr catalysis, we separately mutated the three 
conserved Cys in the yeast enzyme to Ser. Following affinity isolation, wild-type and 
mutant fRMsr proteins were pure as assessed by SDS-PAGE. Mutation of each of Cys 
dramatically affected enzyme activity (the remaining activity was within background). 
Thus, all three Cys were found to be critical for the catalytic activity of fRMsr.  
Wild-type fRMsr (WT) and Cys mutants (Cys91Ser, Cys101Ser, Cys125Ser, 
Cys101/125Ser) were further subjected to Cys targeting by hTrx1 (Cys35Ser mutant)-
immobilized resin (Fig. 2.17.A). Since hTrx1 is an efficient reductant of fRMsr in in vitro 
assays, we hypothesized that mutation of its resolving Cys (i.e., Cys35Ser) would result 
in an intermediate that traps Cys32 (i.e., the catalytic residue) in hTrx1 with the resolving 
Cys in fRMsr.   Interestingly, only WT and Cys101Ser mutant forms were trapped by 
hTrx1 Cys35Ser, suggesting that the remaining Cys (Cys125 and Cys91) are the 
resolving Cys that interact with hTrx1. Cys101Ser mutant, but not other mutants, could 
still form a disulfide between Cys91 and Cys125, reducible by hTrx1. Our model of the 
fRMsr reaction mechanism is shown in Fig. 2.17.B. 
  
 
Fig. 2.16. Structural analysis of fRMsr.
(rmsf) of different fRMsr structures of the molecular dynamic trajectory in the 1 ps 
(curve green), 1-10 ps (blue curve) and 10
shown (A);  rmsf (in Å) is plotted wi
containing the region of interest (residues 80
scale (0.1-1 ps) was observed for Cys125 (indicated by the third arrow, corresponding to 
position 125 in the X-axis), whil
After 1 ps, Cys125 almost arrived in its final position (Fig. 2.15., main text), as can be 
seen in (B). Here, the molecular structure of the three active site Cys for 5 different 
dynamics steps in the range 0
ball and stick representation) was reached quickly, with a considerable displacement of 
all atoms of the residue. After 100 ps, Cys125 was still found in the 1 ps model illustrated 
in (B). 
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-140). Higher deviation in the short time 
e the other two active site Cys were much less mobile. 
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Fig. 2.17. Cys targeting in fRMsr by mutant Trx and the proposed reaction scheme 
of yeast fRMsr. (A) Wild-type fRMsr and its four mutants (Cys91Ser, Cys101Ser, 
Cys125Ser, Cys101/125Ser) were applied onto a resin immobilized with the Cys35Ser 
form of hTrx1. Equal amounts (10 µl) of initial (I), flow-through (F), and DTT-eluted (E) 
fractions were analyzed by western blots with anti-yeast fRMsr antibodies. (B) Proposed 
catalytic mechanism of yeast fRMsr (Type I). Cys101 is proposed to be a catalytic Cys 
directly oxidized by Met-R-SO. Cys125 serves as the resolving Cys that initially forms a 
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disulfide with Cys101 and then transfers this bond to Cys91 via thiol-disulfide exchange. 
The resulting Cys91-Cys125 disulfide is then reduced by Trx or DTT.     
 
2.5. Discussion 
MsrA and MsrB are the best known Msrs that catalyze the reduction of Met-S-SO 
and Met-R-SO residues in proteins, respectively. While these enzymes are well 
characterized structurally and functionally and their critical roles in the repair of oxidized 
Met residues in proteins have been established, how free Met-SO are reduced by cells is 
not fully understood. MsrA does show activity towards free Met-S-SO, but the activity of 
MsrB towards free Met-R-SO is low. Previous studies suggested the occurrence of an 
additional Msr that catalyzes the reduction of Met-R-SO [32, 74, 78]. Recently, Lowther 
and co-workers purified and characterized a third Msr catalyzing Met-SO reduction, 
designated fRMsr [37]. This E. coli enzyme specifically reduced free Met-R-SO in in 
vitro assays and its close homologs occurred in other organisms, including S. cerevisiae, 
suggesting that these homologs may function as fRMsr. The mechanism used by the E. 
coli protein to catalyze the reduction of free Met-R-SO is not known. It is also unclear 
whether E. coli fRMsr homologs indeed possess the same activity and whether fRMsrs 
are responsible for the reduction of bulk of free Met-R-SO in cells. Our work has 
addressed these important questions. 
Comparative genomics analysis of fRMsr homologs in sequenced genomes 
showed a mosaic distribution of this protein. It formed a clearly defined protein family 
whose members occurred in single copies and were present in organisms in all three 
domains of life. Approximately half of the sequenced bacterial genomes contained fRMsr 
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(mostly various proteobacteria and Firmicutes) (Fig. 2.1.). The Firmicutes appear to 
comprise the earliest branching phylum which may be a Gram-positive ancestor for all 
bacteria [81]. Therefore, although many phyla lacked this gene, it is possible that fRMsr 
could have been used in the common ancestor of bacteria. In contrast, it was only 
detected in three closely related archaeal organisms, suggesting either a recent acquisition 
of fRMsr (e.g., by horizontal gene transfer from bacteria) in Thermoplasmales or, less 
likely, a complete loss of it in other archaeal phyla. In eukaryotes, although about half of 
the sequenced organisms possess fRMsr, it is absent from all multicellular organisms, 
including higher plants and animals. It appears that either fRMsr is not essential for these 
organisms or that alternative pathways evolved for Met-R-SO reduction. Besides, two 
variants of fRMsr were identified on the basis of the presence/absence of a conserved Cys 
(Cys91 in yeast fRMsr). Both subtypes had two additional conserved Cys residues that 
were implicated in catalysis [37]. 
Using S. cerevisiae as a model organism, we characterized fRMsr function in vivo 
and in vitro. The analysis of mutant cells lacking fRMsr or combinations of fRMsr and 
MsrA and/or MsrB deletions (i.e., double and triple Msr mutants) revealed that fRMsr 
was responsible for the reduction of free Met-R-SO in yeast cells, whereas MsrA was the 
main protein that reduced free Met-S-SO in this organism.  
Consistent with this function, the fRMsr deletion strain also showed increased 
sensitivity to oxidative stress as well as a reduced lifespan. In addition, even though 
overexpression of fRMsr had almost no effect on yeast lifespan, it protected cells from 
oxidative stress caused by H2O2 treatment. Furthermore, microarray analyses revealed 
elevated expression of fRMsr and MsrA under the conditions of sulfur limitation in cells 
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grown aerobically, whereas MsrB expression did not change. We also found that 
expression of yeast fRMsr in mammalian cells provided them with the ability to reduce 
free Met-R-SO, whereas the initial cells were not able to consume this compound [34]. 
Altogether, these data established an important role of fRMsr in the reduction of free 
Met-R-SO, which is a process by which this protein provides Met for cellular 
metabolism. Taking into account the finding that E. coli fRMsr specifically reduced free 
Met-R-SO [24], we conclude that fRMsr is the main, and may be the only free Met-R-SO 
reductase and that it functions in supplying cells with Met by salvaging oxidized Met. 
Perhaps, the loss of fRMsr in plants and animals can be explained by lower levels of free 
Met sulfoxides in these organisms that evolved protective cover that controls their 
intraorganismal oxygen and ROS levels.   
It can be further inferred that fRMsr, as well as other Msrs, are needed primarily 
under stress conditions. While the triple fRMsr/MsrA/MsrB mutant cells showed a 
reduced lifespan and increased sensitivity to H2O2 treatment, in the absence of stress this 
mutant was viable and grew on the Met-containing media similarly to wild-type cells. 
These data are also consistent with the previous proposal that Msrs and Met contribute to 
the cellular antioxidant system by scavenging ROS via reversible Met oxidation [72].   
To further examine fRMsr, we characterized the recombinant yeast enzyme. As 
expected, it showed specificity for the reduction of free Met-R-SO, but was not active 
with either free Met-S-SO or dabsyl-Met-R-SO residues (the latter mimicking Met-R-SO 
residues in proteins). No fRMsr mutant proteins have previously been characterized, but a 
prediction for the catalytic mechanism was made, based on the structural analysis of the 
E. coli fRMsr, that the three Cys residues are involved in catalysis [37]. Indeed, the role 
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of Cys residues in the catalysis by fRMsr is consistent with the fact that both MsrA and 
MsrB utilize Cys residues for Met-SO reduction. In some MsrA and MsrB forms, these 
Cys are replaced with Sec.   
Through molecular modeling and substrate docking, as well as by employing 
methodologically diverse tools for active site detection, we located the active site in the 
area of Cys101 and Cys125, and both of these residues were implicated in catalysis by 
multiple methods. The specific roles of these residues in catalysis could not be resolved 
by site-directed mutagenesis as both residues were essential for the catalytic activity of 
the enzyme. However, we found that Cys101 is the best candidate catalytic Cys through 
experimental analysis, computational substrate-docking modeling and Cys targeting 
search. We tracked the best scoring models for the binding of Met-R-SO in the catalytic 
site of yeast fRMsr (Fig. 2.12. and Fig. 2.14.). Interestingly, the sulfoxide group of Met-
R-SO protrudes toward sulfur of Cys101, probably leading to oxidation of this residue 
when it attacks the sulfoxide. In contrast, Cys125 may play a supportive role by arranging 
Met-R-SO to interact with Cys101 in our docking model. Furthermore, protein dynamics 
suggested that Cys125, in its stable conformation, comes close to Asp151, in agreement 
with the previously observation on the crystal structure of the reduced active site of yeast 
fRMsr [38]. 
Our computational analysis suggested that Cys125 is flexible and moves between 
two different conformers (Fig. 2.15.), one close to Cys91 (in the oxidized protein) and the 
other near Asp151 (in the reduced enzyme). These observations clearly support the model 
(Fig. 2.17.) wherein the flexible Cys125 is the principal resolving Cys. Its two 
conformations suggest a role in transferring oxidizing equivalents resulting in the Cys91-
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Cys125 disulfide. Consistent with this model, Cys targeting in fRMsr by mutant Trx 
demonstrated that Cys125 and Cys91 could interact with this reductant, whereas Cys101 
could not. Surprisingly, mutation of either of these residues inactivated the enzyme even 
in a DTT-dependent reaction, suggesting that the catalytic residue is not accessible for 
DTT. We propose that the three Cys (Cys91, Cys101 and Cys125) follow classical 
disulfide exchange reactions, initiated by oxidation of Cys101 [75].  
Cys91 is present only in one of two fRMsr forms (Type I), suggesting that it 
cannot be universally essential for catalysis. However, this residue is essential for the 
catalysis by yeast fRMsr. Additional fRMsr forms (Type II) will need to be investigated 
and compared with Type I enzymes to confirm differences in resolving residues.    
Finally, it is clear that fRMsr is the main enzyme responsible for the reduction of 
free Met-R-SO in S. cereivisiae and potentially in other organisms from the three 
domains of life. It is a third member of the group of enzymes that reduce Met sulfoxides. 
Whereas MsrA is responsible for the reduction of both free and protein-based Met-S-SO, 
the reduction of Met-R-SO is carried out by two proteins: MsrB that reduces Met-R-SO 
residues in proteins and fRMsr that accounts for the reduction of free Met-R-SO. All 
three enzymes are widespread indicating importance of catalytic Met sulfoxide reduction 
in biology.  
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CHAPTER 3 
 
Defect in a Methionine Repair Pathway in Mammals and Its Abolition with a Yeast 
Reductase 
 
Note: The results described in this chapter have been published. 
The authors and title of the paper are: 
Lee, B. C., Le, D. T., and Gladyshev, V. N. (2008) Mammals Reduce Methionine-
S-Sulfoxide with MsrA and are Unable to Reduce Methionine-R-Sulfoxide, and this 
Function can be Restored with a Yeast Reductase. J. Biol. Chem. 283, 28361-28369. 
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3.1. Abstract 
Methionine is an essential amino acid in mammals at the junction of methylation, 
protein synthesis and sulfur pathways. However, this amino acid is easily oxidized to a 
mixture of methionine-S-sulfoxide (Met-SO) and methionine-R-sulfoxide (Met-RO). 
Here we report that SK-Hep1 hepatocytes grew on Met-SO and consumed this compound 
by import and MsrA-dependent reduction, but Met-RO could not be used. However, SK-
Hep1 cells expressing a yeast reductase fRMsr proliferated in the presence of either 
sulfoxide, reduced them and showed increased resistance to oxidative stress. Only Met-
RO was detected in plasma of wild-type mice, but both sulfoxides in MsrA knockout 
mice. These results show that mammals can support Met metabolism by reduction of 
Met-SO, that this process is dependent on MsrA, that mammals are inherently deficient in 
Met-RO reduction, and that expression of yeast fRMsr can fully compensate for this 
deficiency. 
 
3.2. Introduction 
Met is an essential amino acid in mammals. Besides its utilization for protein 
synthesis, Met supports cellular S-adenosylmethionine-dependent methylation cycle and 
is used for biosynthesis of Cys and other compounds (Fig. 3.1.) [98-100]. As a central 
metabolite in the global sulfur and methylation pathways, Met homeostasis is subject to 
exquisite regulation that tightly controls fluxes of Met-derived metabolites and Met itself 
[101, 102]. 
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Fig. 3.1. Metabolism of Met and Met sulfoxide in mammalian cells. Protein 
synthesis and methylation and transsulfuration pathways represent major uses of free 
Met. The current study adds information on an additional Met cycle wherein Met is 
oxidized to Met-RO and Met-SO, and only Met-SO can be reduced to Met. Expression of 
yeast fRMsr allows utilization of Met-RO, compensating for deficiency in this function in 
mammals. Abbreviations used: Met; Methionine, Met-RO; Methionine R-sulfoxide, Met-
SO; Methionine S-sulfoxide, MAT; Methionine adenosyltransferase, SAM; S-
adenosylmethionine, SAH; S-adenosylhomocysteine, SAHH; S-adenosylhomocysteine 
hydrolase, CBS; Cystathionine β-synthase, CGL; Cystathionine γ-lyase, MS; Methionine 
synthase, THF; Tetrahydrofolate, DMG; Dimethyl glycine, BHMT; 
Betaine:homocysteine methyltransferase. 
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In spite of extensive information on Met regulation, one pathway critical to Met 
availability and homeostasis did not receive sufficient attention to date. Being a sulfur-
containing amino acid, Met, along with Cys, is highly susceptible to oxidation by ROS 
generated during oxidative stress and normal cellular metabolism. ROS can oxidize both 
free Met and Met residues in proteins resulting in a diastereomeric mixture of Met 
sulfoxides: Met-SO and Met-RO [24, 70]. 
To repair Met-SO and Met-RO residues in proteins, cells have evolved two 
families of enzymes known as MsrA that is specific for Met-SO and MsrB that 
specifically reduces Met-RO [27]. The active sites of both Msr families are better adapted 
for binding Met sulfoxide residues than free Met sulfoxides [70]. Although both MsrA 
and MsrB are capable of reducing free Met sulfoxides [35], a possible contribution of 
these enzymes to the reduction of these amino acids is not known [103].  
Mammals have one MsrA and three MsrB isozymes, with selenoprotein MsrB1 
localized to cytosol and nucleus, MsrB2 to mitochondria and MsrB3 to the endoplasmic 
reticulum [35]. A single MsrA is partitioned into various cellular compartments by 
alternative first exon splicing and folding-dependent cytosolic retention of the protein 
containing a mitochondrial targeting signal [104-107]. MsrA and MsrB are thought to 
both repair oxidatively damaged Met residues and serve as antioxidant proteins, thus 
supporting the role of Met residues in scavenging ROS [17]. Consistent with these ideas, 
deletion of Msrs reduces lifespan in yeast and mice [46, 74], whereas their 
overexpression can increase lifespan in fruit flies and yeast cells [73, 74, 108]. 
In comparison with the repair of oxidized Met residues, reduction of free Met 
sulfoxides in mammals received little attention. On the other hand, several fractions 
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containing proteins distinct from MsrA and MsrB were found to reduce free Met 
sulfoxides in bacteria [32]. Furthermore, by analyzing bacterial cells deficient for MsrA 
and MsrB, two enzymes were identified that act exclusively on free Met sulfoxides. A 
molybdoprotein biotin sulfoxide reductase BisC [109] was found to reduce free Met-SO, 
whereas a GAF domain-containing protein is specific for free Met-RO [37]. 
In this work, we characterized the ability of mammalian cells to reduce free Met 
sulfoxides and examined the roles of MsrA and MsrBs in this process using human SK-
Hep1 hepatocytes as a model system. We found that these cells are deficient in the 
reduction of free Met-RO, but are capable of utilizing Met-SO to satisfy Met needs. We 
further found that MsrA is responsible for the reduction of Met-SO, whereas MsrBs do 
not contribute to the supply of Met from Met sulfoxides. These data were extended to 
animals by finding exclusively Met-RO in the plasma of wild type mice, but both 
diastereomers in the plasma of MsrA knockout mice. Importantly, the inability of 
mammalian cells to reduce Met-RO could be abolished by expressing a yeast enzyme, a 
homolog of bacterial GAF domain fRMsr. Thus, this study both revealed an inherent 
deficiency of mammalian cells in an important antioxidant repair process and identified a 
protein that can fully compensate for this deficiency. 
 
3.3. Experimental procedures 
Preparation of free Met-SO and Met-R-SO. Free Met-SO and Met-RO were 
prepared from mixed L-Met-R,S-sulfoxide (Sigma) according to the method of Lavine 
[110]. To obtain diastereomers of higher purity, we repeated the separation process twice 
for each sulfoxide. Purity of Met-SO and Met-RO was assessed by an HPLC procedure 
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using o-phthalaldehyde (OPA) (Sigma)-derivatized amino acids [24] and found to exceed 
98%. 
Cell culture. SK-Hep1 (ATCC: HTB-52TM) and fRMsr-transfected SK-Hep1 
cells were cultured in DMEM or Met-free DMEM (GIBCO) media, supplemented with 
0.1 mM Met, 0.1 mM Met-RO, 0.1 mM Met-SO, or 0.1 mM Met-RSO. The media also 
contained 10% dialyzed fetal bovine serum (FBS) and an antibiotics-antimycotic mixture 
(GIBCO) of 100 units/ml penicillin G sodium, 100 µg/ml streptomycin sulfate, and 0.25 
µg/ml amphotericin B. Cell culture experiments, with the exception of a proliferation 
assay, were carried out in 6-well plates, and cells were maintained at 37 oC in a 5% CO2 
atmosphere. 
Proliferation Assay. Cell growth was quantified using colorimetric MTS assay 
(Promega). Cells in regular DMEM medium were plated in 96-well plates at 5 × 103 
cells/well, washed with PBS, and specialized DMEM media were added that contained 
Met, Met-SO, Met-RO, or Met-RSO 24 h after plating. Cell proliferation was measured 
at indicated time points from 0 to 96 h in a plate reader. Direct counting of viable cells 
using 0.2% trypan blue was done in 6-well plates.   
An HPLC analysis of media samples. Cells were plated in 6-well plates at 7.5 × 
104 cells/well in 1.5 ml of regular DMEM medium. After 24 h, cells were washed with 
PBS and the medium was changed to modified DMEM containing Met, Met-SO, Met-
RO, or Met-RSO (0.1 mM of each amino acid). 90 µl of medium from each well was 
collected at 0, 24, 48, 72, 96 h and mixed with a 10 µl of 100% TCA. After incubation at 
4 oC for 10 min and centrifugation at 13,000 rpm for 15 min, the supernatant (50 µl) was 
diluted 10 times with distilled water and prepared for OPA derivatization. OPA 
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derivatization of amino acids and HPLC analysis was performed as described [24] with 
minor modifications. The derivatization reagent was freshly prepared as a stock solution 
(40 mg of OPA, 1 ml of methanol, 50 µl of 2-mercaptoehanol, 5 ml of 0.1 M Na2B4O7, 
pH 9.5) at room temperature in a capped amber vial. Sample solutions (2-5 µl) were 
mixed with the OPA derivatization reagent to 100 µl final volume. Following a 2 min 
reaction at room temperature, 50 µl of the mixture were injected onto a Zorbax Eclipse 
XDB-C8 column (4.6×150 mm) initially equilibrated at room temperature with 20 mM 
sodium acetate, pH 5.8 (solvent A) and methanol (solvent B) at a ratio of 88:12 (v/v). 
Met, Met-RO, and Met-SO were separated from other amino acids at room temperature at 
a flow rate of 1.75 ml/min at the same ratio of solvent A and solvent B that was used for 
column equilibration, using an isocratic until 65 min, a linear gradient of 12-40% 
methanol (solvent B) from 65 to 70 min, 40-47% methanol (solvent B) from 70 to 95 
min, and 47-100% methanol (solvent B) from 95 to 98 min. To check for stability of 
OPA-derivatized Met eluted after 80 min, the resulting Met was separated again at room 
temperature at a flow rate of 1.5 ml/min using a linear gradient of 12-40% methanol 
(solvent B) from 0 to 5 min, 40-47% methanol (solvent B) from 5 to 40 min, and 47-
100% methanol (solvent B) from 40 to 45 min. These conditions were also used to 
quantify changes in Met levels in the fRMsr activity assay. Detection was by 
fluorescence of Met derivatives using a Waters 474 scanning fluorescence detector with 
excitation at 330 nm and emission at 445 nm. 
Knockdown of MsrA in SK-Hep1 cells by siRNA. Double stranded siRNAs 
(Dharmacon) for targeting human MsrA mRNA were used to knockdown this gene in 
SK-Hep1 cells. Cells were transfected with siRNA by using DharmaFECT™ 1 
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Transfection Reagent (Dharmacon) according to the manufacturer‘s protocol. 
Proliferation of these cells was assayed 60 h after transfection in comparison with control 
transfected cells.  
Transfection of yeast fRMsr gene into SK-Hep1 cells. A 6 His-tag sequence 
was cloned at the C-terminus of yeast fRMsr, the sequence was inserted into a 
mammalian expression vector, pCI-neo (Promega) and the resulting construct was 
verified by DNA sequencing. SK-Hep1 cells were transfected or cotransfected with the 
expression vector coding for fRMsr and pEGFP-N1 (Clontech) vector or with an empty 
pCI-neo vector and pEGFP-N1 vector using FuGENE 6 Transfection Reagent according 
to the manufacturer’s suggestion. To establish a stable cell line, cells were selected in the 
presence of 800 µg/ml G418 sulfate (Promega), and further maintained in the presence of 
400 µg/ml G418 sulfate. Expression of recombinant fRMsr was verified by western 
blotting using anti-His-tag antibodies and Msr activities were assayed by an HPLC 
method using OPA derivatization. 
Cloning and expression of yeast fRMsr. Putative S. cerevisiae fRMsr 
(YKL069W) cDNA, which encodes a protein homologous to fRMsr from E. coli, was 
amplified from S. cerevisiae genomic DNA and subcloned into pET21b vector (Novagen) 
using primers 5’- AAACATATGATGGGCTCATCAACCGGGTTTC-3’ (sense) and 5’-  
AAGCGGCCGCGACACATGATTTATTAATTAATTTAGCAAG-3’ (antisense). After 
transformation into BL21 (DE3) E. coli, the subcloned sequence was verified by DNA 
sequencing. Cells with the plasmid in 500 ml LB medium containing 100 µg/ml 
ampicillin were grown until OD600 reached 0.6-0.8, followed by addition of IPTG to 0.3 
mM. Protein expression was at 30 oC for 4 h, followed by harvesting cells by 
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centrifugation at 4,000 rpm for 5 min. Cells were washed with PBS and stored at -70 oC 
until use. 
To purify the protein, cell pellet was dissolved in resuspension buffer (Tris-HCl, 
pH 7.5, 15 mM imidazole, 300 mM NaCl), and PMSF was added to a final concentration 
of 0.5 mM. After sonication, supernatant was collected by centrifugation at 8,000 rpm for 
30 min. The supernatant was loaded onto a cobalt talon resin (Clontech) pre-equilibrated 
with resuspension buffer. Following washing with the same buffer, the protein was eluted 
with elution buffer (Tris-HCl, pH 7.5, 300 mM imidazole, 300 mM NaCl). Fractions 
containing yeast fRMsr were pooled together and dialyzed overnight against PBS in a 
dialysis cassette (Pierce). 
Activity assays of fRMsr. Reaction mixture (40 µl) included 50 mM DTT, 1 mM 
substrate (Met-RO or Met-SO), and purified enzyme or cell lysate prepared by treatment 
with CelLyticTMM cell lysis reagent (Sigma). 20 µl of the reaction mixture was mixed 
with 2 µl of TCA and subjected to OPA derivatization as described above and then 
injected onto the column to measure endogenous Met level in the samples. An additional 
20 µl from the same original reaction mixture were incubated at 37 oC for 30 min and 
then subjected to OPA derivatization by the same procedure using TCA. After 
derivatization of the sample (2-5 µl) by adding OPA solution to 100 µl as a final volume, 
50 µl of the mixture were subjected to an HPLC separation as described above.  
Growth of SK-Hep1 cells in various Met and Met sulfoxide media. Growth of 
SK-Hep1 cells was analyzed in modified DMEM media containing Met, Met-SO, Met-
RO, or Met-RSO (0.1 mM of each amino acid) or with no addition of these compounds. 
In addition, media were supplemented or not with 100 nM sodium selenite. Cells were 
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analyzed at 0, 24, 48, and 72 h. The media also contained 10% dialyzed FBS and an 
antibiotics-antimycotic mixture (GIBCO) of 100 units/ml penicillin G sodium, 100 µg/ml 
streptomycin sulfate, and 0.25 µg/ml amphotericin B. Another experiment involving SK-
Hep1 cells was done with cells grown in serum-free modified DMEM medium, 
containing insulin (5 µg/ml) and transferrin (10 µg/ml),  Met or Met-RSO (0.1 mM of 
each amino acid) and 100 nM sodium selenite (or with no addition of this compound), 
and separately in 10% dialyzed FBS-containing DMEM medium containing 0.1 mM Met 
with 100 nM sodium selenite (or not). Cells were analyzed at 0, 24, 48, and 72 h. Assays 
of cell growth were done as described above. 
Analysis of SK-Hep1 and fRMsr-transfected SK-Hep1 cells. SK-Hep1 and 
fRMsr-transfected SK-Hep1 cells were plated in 6-well plates at 7.5 × 104 cells/well in 
regular DMEM medium. The medium was changed to the Met-free DMEM 
supplemented with either Met or individual Met sulfoxides at 24 h after plating. Cells 
were then collected every 24 h until 96 h. Protein concentration was measured by the 
Bradford assay and the samples were probed in western blot assays with polyclonal MsrA 
(kindly provided by Bertrand Friguet), CBS (kindly provided by Ruma Banerjee), and 
ATF3 (Santa Cruz Biotechnology) antibodies. 
Microscopy. Nikon TE-300 Widefield Microscope was used to prepare images of 
SK-Hep1 cells grown on different Met and Met sulfoxide media. Microscopy analyses 
were carried out in the University of Nebraska Microscopy Core Facility. 
75Se Metabolic labeling. SK-Hep1 cells were plated in 6-well plates at 7.5 × 104 
cells/well in 1.5 ml of regular DMEM medium. After 24 h, cells were washed with PBS 
and the medium was changed to modified DMEM media containing Met, Met-SO, Met-
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RO, or Met-RSO (0.1 mM of each amino acid). 0.01 mCi of freshly neutralized [75Se] 
selenious acid (specific activity 1,000Ci/mmol, University of Missouri Research Reactor) 
was added in each well at 48 h after changing the medium and cells were incubated at 37 
oC for 24 h in 5% CO2 atmosphere, followed by harvesting the cells. Cell extracts (30 µg 
of total protein) were electrophoresed on 10% Bis-Tris gels and transferred onto PVDF 
membranes (Invitrogen). The 75Se radioactivity pattern was visualized by using a 
PhosphorImager (GE Health Care).  
Resistance of fRMsr-expressing and control SK-Hep1 cells to oxidative 
stress. SK-Hep1 cells stably transfected with either an empty pCI-neo vector and fRMsr 
construct were plated in 96-well plates at 3.0 × 104 cells/well. The medium was changed 
to a serum-free medium and H2O2 was added to each well at indicated concentrations (0-
1000 µM). Cell viability was measured by using colorimetric MTS assay. 
Mice. MsrA knockout mice [46] were kindly provided by Drs. Rodney Levine 
and Geumsoo Kim (NIH). These and control C57BL6 mice were used for blood 
sampling. In addition, C57BL6 mice, which were subjected to selenium deficiency or a 
control diet containing 0.4 ppm Se in the form of sodium selenite for 8 month, were used.    
HPLC analysis of Met-RO and Met-SO level in mouse blood. Mouse blood 
was centrifuged at 13,000 rpm for 15 min. The supernatant was prepared for OPA 
derivatization without dilution following TCA precipitation and analyzed at isocratic 
flow rate of 2 min/ml at 89:11 (v/v) of 20 mM sodium acetate, pH 5.8 (solvent A) and 
methanol (solvent B) as described in Supplemental Data. 
 
3.4. Results 
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SK-Hep1 cells grow in the presence of Met and Met-SO, but not Met-R-SO. 
To examine the capacity of mammalian cells to provide Met for cellular metabolism by 
Met sulfoxide reduction, human hepatoma SK-Hep1 cells were grown in Met-free 
DMEM medium supplemented with 0.1 mM Met, 0.1 mM Met-SO, 0.1 mM Met-RO or 
0.1 mM mixed Met-RO/Met-SO (Met-RSO) (Figure 3.2.A). SK-Hep1 hepatocytes grew 
best in the presence of Met and could also proliferate in Met-SO and Met-RSO media, 
although at a reduced rate. In contrast, Met-RO did not support growth of SK-Hep1 cells. 
Morphology of cells maintained on Met-SO and Met-RO media was also different (see 
below). After 96 h on the Met-RO medium, SK-Hep1 hepatocytes were long and narrow, 
similar in shape to Met-restricted cells, whereas the cells grown on Met-SO resembled 
those maintained in the presence of Met. These data suggested that SK-Hep1 cells have a 
system for import and reduction of Met-SO, which provides them with Met, whereas 
these cells are unable to utilize free Met-RO.  
To determine whether Met, Met-RO, and Met-SO were consumed by SK-Hep1 
hepatocytes, levels of these compounds were determined in each growth medium at 0, 24, 
48, 72, and 96 h. For this purpose, we developed an HPLC procedure that utilized OPA 
derivatization of free amino acids following TCA precipitation of medium components 
(Figures 3.2.B and 3.3.). We found this method to be superior to the currently available 
procedures for quantitative analysis of free Met sulfoxides and Met. It was recently 
reported [111] that many Met sulfoxide derivatives, such as widely used dabsyl chloride-
reacted forms, are subject to nonenzymatic Met sulfoxide reduction at high temperatures, 
but the corresponding derivatization procedures themselves require heating. In contrast,  
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Figure 3.2. Consumption of Met sulfoxides to sustain cell growth. (A) Growth of SK-
Hep1 hepatocytes on Met and Met sulfoxide media. Cells were grown in Met-free 
DMEM supplemented with 0.1 mM Met (diamonds), 0.1 mM Met-RO (triangles), 0.1 
mM Met-SO (circles), or 0.1 mM Met-RSO (squares). Cell growth was quantified in a 
cell proliferation assay at 0, 24, 48, 72, and 96 h. Error bars represent standard deviations 
from 5 independent experiments. (B) Consumption of Met in Met medium (diamonds), 
Met-SO in Met-RSO medium (squares), Met-RO in Met-RSO medium (triangles), Met-
SO in Met-SO medium (circles), and Met-RO in Met-RO medium (stars) at 0, 24, 48, 72, 
and 96 h. Initial concentration of each amino acid was 0.1 mM. Error bars represent 
standard deviations from 3 independent experiments. 
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Figure 3.3. HPLC analysis of consumption of Met and Met sulfoxides from growth 
media. (A) Upper panel shows Met-SO and Met-RO signals in 0.1 mM Met-RSO 
medium at 0 h and lower panels show changes in Met-SO and Met-RO levels in the same 
medium after growth of SK-Hep1 cells for 96 h. (B) Upper panel shows Met signal in 0.1 
mM Met medium at 0 h and lower panels show change in Met in the same medium after 
96 h growth. (C) Upper panel shows Met-SO signal in 0.1 mM Met-SO medium at 0 h 
and lower panels show change in Met-SO level in the same medium after growing SK-
Hep1 cells for 96 h. (D) Upper panel shows Met-RO signal in 0.1 mM Met-RO medium 
at 0 h and lower panels show change in Met-RO level in the same medium after growing 
SK-Hep1 cells for 96 h. 
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the OPA derivatization process is completed at room temperature after 2-3 min, thus 
avoiding a heating step and associated nonenzymatic Met sulfoxide reduction.  
With this procedure, we found that relative amounts of Met in the Met-
supplemented medium decreased to approximately 60% of the initial level after 96 h. In 
contrast, Met-RO levels were not changed in Met-RO and Met-RSO media at any time 
points. Met-SO was decreased to 88% in the Met-SO-supplemented medium and to 77% 
in the Met-RSO medium (Figure 3.2.B). These data show that SK-Hep1 cells could 
import and consume both Met-SO and Met from the medium to support proliferation. On 
the other hand, consistent with the inability of SK-Hep1 cells to grow on Met-RO, this 
compound was not utilized. Moreover, when cells were grown on Met-RSO, only Met-
SO was consumed.   
SK-Hep1 cell extracts are active in the reduction of Met-SO but not Met-R-
SO. Since both MsrA and MsrB were reported to support low level reduction of free Met 
sulfoxides in in vitro assays [35], it was of interest to examine the roles of these enzymes 
in Met reduction under physiological conditions in mammalian cells. We measured 
specific activities of SK-Hep1 cell extracts for reduction of free Met-RO and Met-SO. No 
free Met-RO reductase activity was detected (it was within background), while the 
activity for free Met-SO reduction was ≈38.6 pmol/min/mg protein (Table 3.1.).  
Role of MsrA in the reduction of free Met-SO. To examine the role of MsrA in 
providing cells with Met by reduction of free Met-SO, we knocked down its expression 
by siRNA. Decreased MsrA expression was verified by western blot assays (Figure 
3.4.A). We found that MsrA-deficient cells grew neither in Met-SO nor Met-RO media, 
whereas Met still supported their growth. Thus, MsrA is responsible for the reduction of  
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Table  3.1. Specific activities of SK-Hep1 cells towards free Met sulfoxides. 
 
Specific activity for each Met-O (pmol/min/mg) 
 Met-RO Met-SO 
**yfRMsr 30015 ± 2652 ND* 
SK-Hep1 ND* 38.6 ± 3.6 
yfRMsr transfected SK-Hep1 46.4 ± 5.0 42.7 ± 5.9 
 
* A signal corresponding to specific activity less than 5 pmol/min/mg is shown as ND 
(Not Detectable) 
** yfRMsr is yeast free methionine R-sulfoxide reductase 
Table shows values ± standard deviations from 3 independent experiments  
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Figure 3.4. Characterization of MsrA-knockdown SK-Hep1 cells. (A) Western blot 
analysis of MsrA in MsrA-knockdown SK-Hep1 cells (lane 1) and control SK-Hep1 cells 
(lane 2). (B) MsrA-knockdown SK-Hep1 cells were grown in media containing 0.1 mM 
Met (closed diamonds), Met-RO (closed circles), Met-SO (closed triangles), or Met-RSO 
(closed squares) for 96 h. Cell growth was measured by an MTS cell proliferation assay 
at 0, 24, 48, 72, and 96 h. Error bars represent standard deviations from 3 independent 
experiments.  
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Figure 3.5. Multiple sequence alignment of yeast fRMsr and its orthologs in bacteria 
and eukaryotes. Conserved residues and predicted Cys involved in catalysis are 
highlighted. Accession numbers: S. cerevisiae (NP_012854), K. lactis (XP_456263), C. 
glabrata (XP_446236), A. oryzae (BAE62132), N. aromaticivorans DSM 12444 
(YP_495413), I. baltica OS145 (ZP_01043850), E. coli F11 (ZP_00723710). 
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Met-SO acquired from the media by SK-Hep1 cells. These data also indicate that none of 
the three mammalian MsrB isozymes contribute significantly to the enzymatic reduction 
of free Met sulfoxides and providing Met to support cell growth.  
Characterization of a yeast enzyme specific for free Met-R-SO. A recent study 
identified a bacterial enzyme specific for free Met-RO [37]. This GAF domain-containing 
protein was designated as fRMsr. We analyzed sequence databases for homologs of this 
protein and found that mammals and other animals lack fRMsr. However, homologs of 
this protein were detected in many lower eukaryotes (Figure 3.5.). We cloned fRMsr 
homolog from S. cerevisiae (designated yfRMsr) and expressed it in E. coli as a His-
tagged protein. The recombinant protein was soluble and had the expected molecular 
weight as determined by SDS-PAGE and mass spectrometry (data not shown), whereas 
the native yeast protein functioned as fRMsr in S. cerevisiae cells. The recombinant yeast 
fRMsr protein exhibited high activity towards free Met-RO (≈33 nmol/min/mg protein), 
whereas it was inactive with Met-SO as well as with dabsyl-Met-RO and dabsyl-Met-SO. 
Yeast fRMsr-expressing SK-Hep1 cells grow on Met-R-SO. Yeast fRMsr was 
stably expressed in SK-Hep1 cells in the form of His-tagged protein, and its expression 
was verified in western blot assays with antibodies specific for His-tag (Figure 3.6.A). 
Specific activity of fRMsr-transfected cells for Met-RO was ≈46.4 pmol/min/mg protein 
and the activity of these cells towards Met-SO was ≈42.7 pmol/min/mg protein (Table 
3.1.). The transfected cells grew on Met-SO or Met-RO media, and their growth was 
essentially indistinguishable from that of cells grown in the presence of Met (Figure 
3.6.B). Morphology of fRMsr expressing cells on the Met-RO-supplemented medium 
was similar to that of cells grown on Met (Figure 3.7.). Thus, yeast fRMsr expressed in  
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Figure 3.6. Characterization of SK-Hep1 cells expressing yeast fRMsr. (A) Western 
blot analysis of SK-Hep1 cells stably expressing yeast His-tagged fRMsr (lane 1) and 
control SK-Hep1 cells (lane 2) with anti-His antibodies. (B) Yeast fRMsr-transfected SK-
Hep1 cells were grown in media containing 0.1 mM Met (closed diamonds), 0.1 mM 
Met-RO (closed circles), 0.1 mM Met-SO (closed triangles), or 0.1 mM Met-RSO (closed 
squares) until 96 h. Cell growth was measured by an MTS cell proliferation assay at 0, 
24, 48, 72, and 96 h. (C) Resistance of fRMsr-expressing SK-Hep1 cells to hydrogen 
peroxide treatment. Control (closed diamonds) and fRMsr-expressing SH-Hep1 (closed 
squares) cells were treated with indicated concentrations of hydrogen peroxide and their 
viability was assayed at 24 h. Error bars show standard deviations from 3 independent 
experiments. 
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Figure 3.7. Morphology of cells grown on sulfoxide media. (A) An image of SK-Hep1 
cells grown in the Met-SO medium for 96 h. (B) An image of SK-Hep1 cells grown in 
Met-RO medium for 96 h. (C) An image of SK-Hep1 cells stably expressing yeast fRMsr 
grown in Met-RO medium for 96 h.  
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SK-Hep1 cells could reduce free Met-RO in quantities sufficient to compensate for Met 
deficiency. These data also indicated that Met-RO could be imported into SK-Hep1 cells 
from the medium. 
Increased resistance of fRMsr-expressing SK-Hep1 cells to oxidative stress. 
SK-Hep1 cells expressing yeast fRMsr were further examined for resistance to oxidative 
stress by subjecting them (and control cells) to hydrogen peroxide treatment. At higher 
concentrations of hydrogen peroxide (above 400 µM), fRMsr-expressing cells showed 
significantly higher viability than control cells (Figure 3.6.C). Thus, yeast fRMsr 
protected SK-Hep1 cells from oxidative stress caused by hydrogen peroxide treatment. 
The increased resistance of transfected cells to oxidative stress is likely due to reduction 
of free Met-RO formed by Met oxidation in the presence of hydrogen peroxide. In 
addition, these data indicate that reversible oxidation and reduction of free Met-RO (and 
by analogy free Met-SO) provides mammalian cells with an antioxidant defense system.  
MsrA and selenoprotein expression in cells grown on Met and Met sulfoxide 
media. We tested whether expression of MsrA is regulated by availability of Met or Met 
sulfoxides by maintaining cells on the corresponding growth media (Figure 3.8.A). 
Although levels of this enzyme slightly decreased after 96 h growth of SK-Hep1 cells, 
this change was observed in all samples and we did not find significant differences in 
MsrA expression among samples examined. Thus, MsrA expression was not influenced 
by Met sulfoxide levels in cell culture media. We also tested if addition of Met sulfoxides 
regulates expression of selenoproteins, many of which are important antioxidant enzymes 
or redox regulators (Figure 3.8.B). We metabolically labeled SK-Hep1 cells with 75Se 
and examined selenoprotein patterns. No difference was observed among cells grown on  
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Figure 3.8. CBS, ATF3, MsrA, and selenoprotein expression in SK-Hep1 cells grown 
in Met and Met sulfoxide media. (A) Western blot analysis of MsrA in SK-Hep1 cells 
grown in media containing 0.1 mM Met, Met-RO, or Met-SO at 0, 24, 48, 72, and 96 h. 
(B) Metabolic labeling of SK-Hep1 cells grown in media containing Met, Met-RO, Met-
SO, or Met-RSO, with 75Se. Cell extracts were analyzed by SDS-PAGE and the 75Se 
pattern visualized with a PhosphorImager (upper panel). Migration of major 
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selenoproteins, thioredoxin reductase1 (Tr1) and glutaredoxin peroxidase1 (GPx1) is 
indicated. Migration of MsrB1 is also shown, and the corresponding area of the gel is 
enlarged in the middle panel. Lower panel shows protein loading. (C) Western blot 
analysis of CBS in SK-Hep1 cells grown in media with 0.1 mM Met, Met-RO, Met-SO, 
or Met-RSO at 0, 24, 48, 72, and 96 h. (D) Western blot analysis of CBS in fRMsr-
expressing SK-Hep1 cells grown in media containing 0.1 mM Met-RO or Met-SO at 0, 
24, 48, 72, and 96 h. (E) Western blot analysis of ATF3 in SK-Hep1 cells grown in media 
with 0.1 mM Met, Met-RO, or Met-SO at 72 h. (F) Western blot analysis of ATF3 in 
fRMsr-expressing SK-Hep1 cells grown in media containing 0.1 mM Met, Met-RO or 
Met-SO at 72 h. 
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Figure 3.9. Growth of SK-Hep1 cells in selenium-deficient media. (A and B) Cells 
were grown in Met-free medium supplemented with Met (diamonds), Met-RO (circles), 
Met-SO (triangles), Met-RSO (squares) (0.1 mM of each amino acid), or with no addition 
of these compounds (stars) for 0, 24, 48, or 72 h. FBS and insulin/transferin media 
supplemented with Met or Met sulfoxides were also used. (A) 100 nM Se was added to 
each medium. (B) No Se was added. (C) The following cell growth conditions were 
examined: 10% FBS and 0.1 mM Met (closed diamonds); 10% FBS, 0.1 mM Met, and 
100 nM Se (open diamonds); insulin, transferrin, and 0.1 mM Met (closed squares); 
insulin, transferrin, 0.1 mM Met, and 100 nM Se (open squares); insulin, transferrin, and 
0.1 mM Met-RSO (closed triangles); and insulin, transferrin, 0.1 mM Met-RSO, and 100 
nM Se (open triangles). Error bars represent standard deviations from 3 independent 
experiments. 
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Met, Met-RO, Met-SO and Met-RSO media. Addition of selenium (100 nM sodium 
selenite) also did not influence cell growth on Met and Met sulfoxide in FBS-
supplemented and insulin/transferrin (Figure 3.9.) media. These data further argue against 
the role of selenoprotein MsrB1, which is a major peptide Met-RO reductase in 
mammals, in reduction of free Met sulfoxides.  
CBS expression in cells grown on Met and Met sulfoxide media. Met 
restriction in SK-Hep1 cells is known to reduce cystathionine beta synthase (CBS) levels 
by decreasing availability of S-adenosylmethionine, which stabilizes CBS [101]. Thus, 
this protein can be viewed as a marker of S-adenosylmethionine status (and therefore Met 
availability). We examined expression of CBS in cells grown on Met and Met sulfoxide 
media (Figure 3.8.C and D). In the presence of Met-RO, SK-Hep1 cells reduced 
expression of this protein, whereas the cells grown on Met maintained stable CBS levels. 
In cells grown on the Met-SO medium, CBS levels were decreased, suggesting that 
although MsrA supports proliferation of SK-Hep1 cells by providing them with Met, 
these cells still suffer from Met deficiency (Figure 3.8.C). Interestingly, fRMsr-
expressing cells grown on Met-RO had normal CBS levels (Figure 3.8.D). Thus, fRMsr 
can fully compensate for the lack of Met-RO reductase activity in SK-Hep1 hepatocytes 
and provide these cells with full amount of Met needed for cellular metabolism.  
ATF3 expression in cells grown on Met and Met sulfoxide media. Activating 
transcription factor 3 (ATF3) is known to be expressed at low levels in normal and 
quiescent cells, but is rapidly induced by various stresses, such as amino acid deprivation, 
oxidative stress, and ER stress [112-114]. ATF3 is also relevant to the control of cell 
proliferation and pathway crosstalk regulation [115]. Interestingly, SK-Hep1 cells grown 
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on Met-RO for 72 h showed low expression levels of ATF3 as compared with cells on 
Met or Met-SO (Figure 3.8.E), suggesting that cells grown on Met-RO had defects in 
metabolism and proliferation due to limitation of Met. Importantly, SK-Hep1 cells 
quiescent on Met-RO recovered normal metabolic activity and ability to proliferate when 
transfected with a construct coding for yeast fRMsr (Figures 3.6.B and 3.8.F). 
Met-SO and Met-RO levels in mouse plasma. To test if differences in Met-SO 
and Met-RO consumption and reduction that were evident in cell culture experiments are 
also observed in an animal system, we analyzed Met-SO and Met-RO levels in mouse 
plasma. Met-SO was not detectable in plasma of wild type mice, whereas Met-RO 
concentration was ≈9.1 ± 0.7 µM (quantified by providing known amounts of Met-RO 
and Met-SO standards to plasma samples) (Figures 3.10. and 3.11.A). To test if MsrA is 
responsible for low systemic Met-SO in mouse blood, we examined MsrA knockout 
mice. These mice had similar levels of Met-SO and Met-RO in plasma (Figures 3.10. and 
3.11.B). Met-SO concentration was determined to be ≈14.6 ± 3.1 µM and Met-RO was ≈ 
9.8 ± 1.6 µM (Figures 3.10. and 3.11.C). These data show that deletion of MsrA caused a 
remarkable increase specifically in Met-SO levels, in indicating that MsrA is responsible 
for low levels of Met-SO in plasma of wild type mice. We also subjected wild type mice 
to selenium deficiency, which reduced MsrB1 to undetectable levels in liver (data not 
shown). Under these conditions, plasma Met-SO was ≈3.7 ± 0.6 µM and Met-RO was 
≈16.2 ± 2.4 µM (Figures 3.10. and 3.11.D), indicating that both sulfoxides showed 
slightly increased levels. Besides MsrB1, several selenoproteins serve as antioxidant 
proteins and show reduced expression in selenium deficiency, resulting in increased 
oxidative stress. Thus, slight elevation in both Met-SO and Met-RO under conditions of  
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Figure 3.10. Analysis of Met-SO and Met-RO in mouse plasma. Concentrations of 
Met-SO and Met-RO were determined in plasma of wild type, heterozygous MsrA 
knockout (+/-), homozygous MsrA knockout (-/-), and selenium-deficient (SD) mice. 
Error bars represent standard deviations from 4 independent experiments.  
 
81 
 
 
Figure 3.11. HPLC analysis of Met-SO and Met-RO in mouse plasma. Met-SO and 
Met-RO were examined by an HPLC assay in plasma from (A) wild type, (B) 
heterozygous MsrA knockout, (C) homozygous MsrA knockout, and (D) selenium-
deficient (SD) mice. 
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low dietary selenium is due to overall increased oxidative stress caused by systemic 
selenoprotein deficiency.  
 
3.5. Discussion 
Prior to this study, there was little understanding of the pathway for reduction of 
free Met-SO and Met-RO in mammalian cells. Although both Met residues and free Met 
are known to be susceptible to oxidation by ROS, and the reduction of Met sulfoxide 
residues is carried out by four enzymes in mammals, whether free Met sulfoxides are 
reduced or wasted was not known. Surprisingly, analysis of human SK-Hep1 hepatocytes 
grown on media containing Met, Met-RSO or individual Met sulfoxide diastereomers 
showed a significant difference in cell proliferation and Met sulfoxide consumption 
between Met-SO and Met-RO (Figure 3.2.). Met-SO, but not Met-RO, supported growth 
of SK-Hep1 cells and was consumed from the medium. In addition, cell extracts of SK-
Hep1 cells showed high free Met-SO reductase activity, whereas free Met-RO activity 
was not detected (Table 3.1.). Certainly, MsrA was an obvious candidate for the role in 
free Met-SO reduction, and further experiments confirmed this idea as MsrA-deficient 
SK-Hep1 cells were no longer able to utilize free Met-SO and could not grow on either 
Met sulfoxide. These findings, as well as experiments with selenium deficiency and 
supplementation in SK-Hep1 hepatocytes, also demonstrated that none of three 
mammalian MsrBs had a role in providing these cells with Met by enzymatic free Met 
sulfoxide reduction.  
We were able to further extend these observations from cell culture to animal 
models. Plasma samples from wild type mice had undetectable Met-SO, whereas bulk of 
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its Met sulfoxide occurred in the form Met-RO (~9 µM). Moreover, MsrA knockout mice 
had both diastereomers at similar levels, indicating a specific elevation in Met-SO. Thus, 
not only hepatocytes, but also animals were deficient in Met-RO reduction and 
accumulated this compound in blood. In addition, low levels of Met-SO were clearly due 
to reduction of this compound by MsrA. We also found that subjecting wild type mice to 
selenium deficiency slightly elevated both diastereomers, likely due to overall increased 
oxidative stress caused by systemic selenoprotein deficiency.  This finding again 
excluded the role of MsrB1 in reducing Msr-RO in mice. 
A recent report by Lowther and collaborators [37] identified an enzyme, fRMsr, 
that catalyzes the reduction of free Met-RO in E. coli. However, our sequence analyses 
revealed that mammals lack this protein. Nevertheless, fRMsr homologs were detected in 
a variety of prokaryotes as well as in many single celled eukaryotes. We characterized an 
fRMsr homolog from S. cerevisiae, which showed robust free Met-RO reductase activity. 
Furthermore, SK-Hep1 cells expressing this protein grew equally well on Met and Met-
RSO media (Figure 3.6.B). Thus, fRMsr could fully compensate for inability of SK-Hep1 
cells to reduce free Met-RO and could provide these cells with Met in quantities 
sufficient for cell growth. In addition, we observed increased resistance of fRMsr-
expressing cells to hydrogen peroxide treatment, suggesting that reduction of free Met 
sulfoxides provides cells with an antioxidant defense as previously proposed by Levine, 
Stadtman and collaborators (15). In view of such an important function, it is puzzling 
why mammals lack fRMsr. Perhaps, environment at the time when animals evolved could 
have played a role. Single-celled organisms, including prokaryotes and lower eukaryotes, 
exhibit rapid growth if provided with necessary resources. However, feast is quickly 
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replaced by starvation due to rapid consumption. Thus, single-celled organisms are often 
faced with Met deficiency and the resulting low levels of S-adenosylmethionine, 
glutathione and other compounds are dependent on sufficient Met supply. Moreover, 
many single-celled organisms directly contact with air, with consequent higher oxidative 
stress than in multicellular organisms, which are in part protected by cover of their skin 
and controlled delivery of molecular oxygen for cellular metabolism. Thus, fRMsr 
function may be needed by single-celled organisms more than by multicellular 
organisms. However, once the enzyme is lost, the ability for Met-RO reduction might be 
difficult to replace, and mammalian cells are now faced with this defect.  In this regard, 
the finding that an yeast reductase fRMsr can fully compensate for deficiency in Met-RO 
reduction could provide avenues for correcting this defect in mammals and other animals. 
Met is an essential amino acid in mammals, which is exclusively derived from 
food sources and linked to many metabolic processes, including protein synthesis, 
methylation, sulfur metabolism and ROS scavenging. In particular, Met metabolism has 
an important role in the synthesis of antioxidant compounds, such as cysteine, taurine and 
GSH, through the transsulfuration pathway in liver, kidney, and small intestine. Thus, 
free Met plays a role in antioxidant defense not only by scavenging ROS (through 
reversible oxidation), but also as precursor of other antioxidant compounds. 
Finally, our findings have direct implication to the use of drugs containing 
methionine sulfoxides. Since MsrA is known to reduce methylsulfoxides, many such 
drugs should be MsrA substrates, but only the S epimers of these molecules [32].  In 
contrast, the reduction of the corresponding R epimers would not be possible in 
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mammalian cells. Thus, depending on the need for their reduction (i.e., whether to 
stabilize or activate the drug), R or S epimers of these drugs could be used.  
In conclusion, this work revealed the ability of mammalian cells to utilize free 
Met sulfoxides; however, of the two diastereomers, only Met-SO is consumed in 
sufficient quantities, and this occurs in a MsrA-dependent manner. In contrast, mammals 
are deficient in the reduction of free Met-RO due to loss of fRMsr in animals during 
evolution. Importantly, we found that this potential Achilles heel of the mammalian 
antioxidant repair system could be abolished by expression of a yeast fRMsr, suggesting 
strategies for improved protection of mammals from oxidative stress, disease and aging 
and the use of drugs containing specific diastereomers of methionine sulfoxides.   
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CHAPTER 4 
 
Reduction of sulfoxide-containing drugs by methionine sulfoxide reductases 
 
Note: The results described in this chapter have been written up for publication. 
The authors and title of the paper are: 
Lee, B.C. and Gladyshev, V. N. (2010) Reduction of sulfoxide-containing drugs 
by methionine sulfoxide reductases, manuscript in preparation 
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4.1. Abstract 
Methionine residues in proteins are susceptible to oxidation, but their oxidized 
forms, Met-S-SO and Met-R-SO, can be reduced back to Met by MsrA and MsrB, 
respectively. In addition, free Met-S-SO and free Met-R-SO can be reduced by MsrA and 
fRMsr, respectively, The three known Msrs account for the reduction of methylsulfinyls 
in Met sulfoxides. Some drugs and natural compounds also contain methylsulfide or 
methylsulfinyl groups, the latter existing as a mixture of R-sulfoxide and S-sulfoxide 
forms. We examined several such compounds and drugs and found that mesoridazine, 
triclabendazole sulfoxide, and sulmazole were reduced by mouse MsrA, but not by 
mouse MsrB2 or yeast fRMsr. S-sulforaphane, a natural compound, was also reduced 
only by mouse MsrA, whereas R-sulforaphane could not be reduced by any Msr. On the 
other hand, omeprazole and biotin d,l-sufoxide, which contain sulfoxide groups 
connected to bulky groups, were not reduced by Msrs. Finally, DMSO was reduced by 
mouse MsrA, but not by mouse MsrBs. These results reveal the deficiency in mammals 
with regard to reduction of R-methylsulfinyls in drugs and other compounds, which may 
have important therapeutic applications. 
 
4.2. Introduction 
Met contains a methylsulfide group in its side chain, which is highly susceptible 
to oxidation by ROS. Oxidation of this functional group may disrupt structure and 
function of proteins, which in turn contributes to the occurrence of diseases associated 
with accumulation of oxidatively damaged proteins [27, 39, 116, 117]. Several enzymes 
evolved to minimize the deleterious effect of oxidative stress, such as glutathione 
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peroxidase and thioredoxin reductase [1]. Methionine sulfoxide (MetO), formed by 
oxidation of methylsulfide in Met, is also subject to reversible redox conversion. A key 
enzyme in this process is methionine sulfoxide reductase (Msr), which reduces Met 
sulfoxide back to Met [1, 16, 27, 118]. An important point is also that Msr and Met 
together may scavenge ROS through cyclic oxidation and reduction of Met [16, 27, 118].  
Msrs are members of two families, MsrA and MsrB, which are specific for Met-
S-SO and Met-R-SO, respectively [16, 27, 118]. Recent studies identified a new Msr 
type, fRMsr, which reduces free Met-R-SO, although this protein is present only in 
unicellular organisms [33, 34, 37]. All Msrs, including MsrA, MsrB, and fRMsr, are 
specific for one enantiomer, and MsrA and MsrB are fused into a single protein in some 
prokaryotes, such as Shewanella oneidensis [134]. Thus, the three Msrs have different 
substrates, whereas the final products of the reduction are the same (e.g., Met). Mammals 
have four Msr proteins, MsrA, MsrB1, MsrB2, MsrB3A, and MsrB3B [63]. Although 
other types of methionine sulfoxide reductases, such as fRMsr and BisC, were 
characterized in bacteria [33, 37, 109], mammals do not possess homologs of these 
proteins. Thus, only these four Msrs are responsible for the reduction of methylsulfinyl 
group in Met-R,S-SO in mammals.  
Like Met, many drugs and natural compounds contain methylsulfide groups and 
are likely subject to reversible oxidation and reduction in vivo. Liver is a major organ for 
drug metabolism and contains various enzymes that are responsible for oxidation, 
reduction, hydrolysis, conjugation, and other modifications [119]. For example, 
cytochrome p450 (Cyp450)  enzymes are known for their roles in oxidative modification 
of drugs [120]. Methylsulfinyl group is another type of modification that can be 
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generated by oxidation of methylsulfide-containing compounds upon exposure to 
hydrogen peroxide, but the fate of methylsulfinyls is not clear [121].  
Several studies proposed that Msrs might be involved in the reductive metabolism 
of methylsulfinyl-containing drugs. For example, it was found that an unknown renal 
enzyme could reduce sulindac to sulindac sulfide in a thioredoxin-dependent manner 
[109]. Another research group reported that sulindac can be reduced by E. coli MsrA and 
a membrane-associated Msr protein fraction [26]. These results suggest that Msrs 
participate in the reductive metabolism of sulindac sulfoxide in mammals.  
It was suggested that hydrophobic pockets in the active sites of MsrA and MsrB 
play a role in substrate binding and catalysis, whereas hydrophilic groups participate in 
stabilization of protonated sulfoxide [23]. MsrA is known for its broad substrate 
specificity, e.g., it reduces peptide-bound Met-S-SO, free Met-S-SO, N-acetyl-
methionine-S-sulfoxide, dimethyl sulfoxide, ethionine-S-sulfoxide, S-sulindac and other 
substrates, while MsrB is specific for peptide-bound Met-R-SO and has very low activity 
with free Met-R-SO. Some methylsulfinyl groups in drugs and other compounds are 
linked to bulky groups, so their overall structure would be too different from that of Met-
SO, suggesting they will not be subtrates for either MsrA or MsrB [23, 122]. In the 
present study, we investigated reduction of sulfoxide-containing drugs and compounds by 
mouse MsrA, MsrBs and yeast fRMsr. This study addressed the stereoselective reduction 
of sulfoxide-containing compounds and provided useful information for future design of 
drugs with improved efficacy. 
 
4.3. Experimental procedures 
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Cloning, expression, and purification of mouse MsrA, mouse MsrB2, yeast 
fRMsr, and mouse MsrB1-Cys. Previously generated expression constructs for mouse 
MsrB1-Cys [50], mouse MsrB2 [50], mouse MsrA [107], and yeast fRMsr [33] were 
transformed into BL21 (DE3) E. coli. Cells with the plasmid in 500 ml LB medium 
containing 50 µg/ml ampicillin were grown until OD600 reached 0.6-0.8, followed by 
addition of IPTG to 0.3 mM. Protein expression was at 30 oC for 4 h, followed by 
harvesting cells by centrifugation at 4,000 rpm for 5 min. Cells were washed with PBS 
and stored at -70 oC until use. 
To purify proteins, cell pellets were resuspended in 50 mM Tris-HCl, pH 7.5, 15 
mM imidazole, 300 mM NaCl, and PMSF was added to a final concentration of 0.5 mM. 
After sonication, supernatants were collected by centrifugation at 8,000 rpm for 30 min. 
The supernatants were loaded onto a cobalt Talon resins (Clontech) pre-equilibrated with 
resuspension buffer. Following washing with the same buffer, proteins were eluted with 
elution buffer (Tris-HCl, pH 7.5, 300 mM imidazole, 300 mM NaCl). Fractions 
containing yeast Msrs were pooled together and dialyzed overnight against PBS in a 
dialysis cassette (Pierce). 
Preparation of mesoridazine, triclabendazole sulfoxide, sulmazole, biotin d,l-
sulfoxide, R- and S-sulforaphane-DTT, and omeprazole. Mesoridazine (Sigma), 
triclabendazole sulfoxide (AmXpress), sulmazole (Sigma), biotin d,l-sulfoxide (kindly 
provided by Dr. Janos Zempleni), sulmazole (Sigma) were prepared in either ethanol or 
distilled water prior to enzyme assays. In addition, R- or S-sulforaphane (LKT 
Laboratories, Inc) were incubated with DTT as a 1 to 10 ratio for 1 h at 37 °C and then 
used in the enzyme reaction.  
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Activity assays of mouse MsrA, mouse MsrB2, and yeast fRMsr.  Mouse 
MsrA, mouse MsrB2, and yeast fRMsr were used in the reduction assay in the presence 
of DTT. Dabsylated Met-R-SO, dabsylated Met-S-SO, and free Met-R-SO were prepared 
as described above. In the case of DTT-dependent reaction, the reaction mixture (100 µl) 
contained 50 mM sodium phosphate, pH 7.5, 50 mM NaCl, 20 mM DTT, 500 µM Met-O 
(dabsylated Met-R-SO, dabsylated Met-S-SO, or free Met-R-SO), and purified proteins. 
Reactions were carried out at 37 °C for 30 min and then were stopped by adding 200 µl 
of acetonitrile. Reduced products were analyzed by HPLC as described previously [33, 
34]. 
Reduction assays of omeprazole and biotin d,l-sulfoxide. Mouse MsrA, mouse 
MsrB2, mouse MsrB1-Cys and yeast fRMsr were used in the reduction assay in the 
presence of Trx reductase/Trx/NADPH. A reaction mixture (100 µl) contained 50 mM 
sodium phosphate, pH 7.5, 50 mM NaCl, 6.8 µM E. coli Trx (Sigma), 0.2 mM NADPH, 
0.4 µM E. coli Trx reductase, 500 µM each substrate and purified proteins. Reactions 
were carried out at 37 °C for 60 min. NADPH reduction was measured every 10 min at 
340 nm with plate reader Elx808IU (Bio-Tek).  
Analysis of reduction of drugs using ion-spray mass spectrometry, HPLC, 
and GC. Mouse MsrA, mouse MsrB2, mouse MsrB1-Cys and yeast fRMsr were used in 
the reduction assay in the presence of DTT or Trx reductase/Trx/NADPH. Mesoridazine, 
triclabendazole sulfoxide, sulmazole, omeprazole, biotin d,l-sulfoxide, DMSO, R-
sulforaphane-DTT, and S-sulforaphane-DTT were used as substrates. In the case of DTT-
dependent reaction, the reaction mixture (100 µl) contained 50 mM sodium phosphate, 
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pH 7.5, 50 mM NaCl, 20 mM DTT, 500 µM each drug substrates (5 mM R- or S-
sulforaphane-DTT) and purified proteins. In the Trx-dependent reaction, the reaction 
mixture (100 µl) contained 50 mM sodium phosphate, pH 7.5, 50 mM NaCl, 6.8 µM E. 
coli Trx (Sigma), 0.2 mM NADPH, 0.4 µM E. coli Trx reductase, 500 uM each drug 
substrate and purified proteins. The reactions were carried out at 37 °C for 10, 20, 30, 40, 
50, and 60 min for triclabendazole sulfoxide and sulmazole, 2.5, 5, 10, 15, 30, 45, and 60 
min for mesoridazine and 30 min for other drugs and then stopped by adding 300 µl 
acetonitrile (ACN) (mesoridazine reaction), 900 µl ethanol (DMSO reaction), or 10 µl 
trichloroacetic acid (50 %) for other drugs. After 5 min incubation at 4 °C, the mixtures 
were centrifuged at 13,000 rpm for 20 min. Then, supernatant was taken for further ion-
spray mass spectrometry and HPLC analysis.  
Ion-spray mass spectrometry analysis. MS and MS/MS spectra were obtained 
on a Sciex API-III triple-quadrupole mass spectrometer equipped with an atmospheric 
pressure ionization source. The mass spectrometer was operated in the negative mode. 
The samples (20 µl) were introduced in distilled water/acetonitrile/formic acid (50:50:0.3 
by volume) (180 µl). Scanning was done in the range of m/z 100 to 1000. 
HPLC analysis for mesoridazine and its reduced form. 50 µl supernatant from 
the mesoridazine reduction assay was injected onto ZORBAX RX-C18 column (4.6×150 
mm) (Agilent). In this assay, solvent A (20 mM sodium acetate, pH 4.0) and solvent B 
(ACN) were used. Mesoridazine and thioridazine were separated from other compounds 
at room temperature at a flow rate of 1 ml/min using a linear gradient of 30 – 50 %  
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Fig. 4.1. Expression and activity assays of Msrs and a list of methylsulfinyl-
containing drugs and compounds. A. Mouse MsrA (27.1 kDa), mouse MsrB2 (lacking 
signal peptide) (15.8 kDa), and yeast fRMsr (20.8 kDa) were expressed in E.coli, purified 
and analyzed by SDS-PAGE. B. Specific activities of mouse MsrA for dabsylated Met-S-
SO, mouse MsrB2 for dabsylated Met-R-SO, and yeast fRMsr for free Met-R-SO with 
DTT as a reductant. C. Methylsulfinyl-containing drugs and natural compounds.  
  
94 
 
solvent B from 0 to 30 min, and 50 – 100 % solvent B from 30 to 33 min. Detection was 
at 254 nm using a Waters 996 PDA detector. 
HPLC analysis of triclabendazole sulfoxide and its reduced form. 25 µl 
supernatant from the reaction with triclabendazole sulfoxide was mixed with 25 µl 
distilled water containing 0.05 % trifluoroacetic acid (TFA) prior to injection onto 
ZORBAX RX-C18 column (4.6×150 mm) (Agilent). For this analysis, solvent A (0.1 % 
TFA in distilled water) and solvent B (ACN including 0.1 % TFA) were used. 
Triclabendazole and triclabendazole sulfoxide were separated from other compounds at 
room temperature at a flow rate of 1.5 ml/min using an isocratic of 45 % solvent B until 8 
min and then a linear gradient of 45 – 100 % solvent B from 8 to 10 min. Detection was 
at 254 nm using a Waters 996 PDA detector.  
HPLC analysis of sulmazole and its reduced form. 2.5 µl supernatant from the 
reaction with sulmazole was mixed with 47.5 µl of 20 mM sodium phosphate in distilled 
water (pH 7.4)/ACN/distilled water (2:1:3, v/v) prior to injection onto ZORBAX RX-C18 
column (4.6×150 mm) (Agilent). In this assay, solvent A (20 mM sodium phosphate in 
distilled water, pH 7.4/ACN, 2:1 ratio in v/v) and solvent B (ACN) were used. Sulmazole 
and its reduced form were separated from other compounds at room temperature at a flow 
rate of 1.5 ml/min using an isocratic of 100 % solvent A until 15 min. Detection was by 
fluorescence using a Waters 474 scanning fluorescence detector with excitation at 330 
nm and emission at 370 nm. 
HPLC analysis of R- or S-sulforaphane-DTT conjugation and its reduced 
form. 10 µl supernatant from the reaction with R- or S-sulforaphane-DTT conjugate was  
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Fig. 4.2. Mass spectrometry analysis of mesoridazine reduction by Msrs. A. 
Mesoridazine reduction by mouse MsrA. Mesoridazine appears at m/z: 387.1 and its 
reduced form (thioridazine) at m/z: 371.2. B. Mesoridazine reduction by mouse MsrB2. 
C. Mesoridazine reduction by yeast fRMsr. 
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Fig. 4.3. Reduction of mesoridazine by Msrs and their specific activities. Reduction 
of mesoridazine by mouse MsrA, mouse MsrB2, and yeast fRMsr was analyzed using 
HPLC and separated substrate and product peaks were confirmed by mass spectrometry. 
A. HPLC analysis of mesoridazine reduction by mouse MsrA with DTT as a reductant. 
Mesoridazine was detected as m/z: 387.6 and its reduced form (thioridazine) as m/z: 
371.6. B. HPLC analysis of mesoridazine reduction by mouse MsrB2 using DTT as a 
reductant. C. HPLC analysis of mesoridazine reduction by yeast fRMsr using DTT as a 
reductant. D. Specific activities of mouse MsrA, mouse MsrB2, and yeast fRMsr in the 
reduction of mesoridazine using either DTT or TR/Trx/NADPH (shown as Trx) as 
reductants (n = 3). 
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Fig. 4.4. Time course of product formation in the reduction of mesoridazine, 
triclabendazole sulfoxide, sulmazole by mouse MsrA. Reduction of each compound by 
MsrA was quantified at each time point using HPLC. A. Mesoridazine. B. 
Triclabendazole sulfoxide. C. Sulmazole. 
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mixed with 40 µl distilled water containing 0.06 % TFA prior to injection onto ZORBAX 
RX-C18 column (4.6×150 mm) (Agilent). In this assay, solvent A (0.06 % TFA in 
distilled water) and solvent B (ACN including 0.06 % TFA) were used. R- or S-
sulforaphane-DTT conjugate or its reduced form were separated from other compounds 
at room temperature at a flow rate of 1.0 ml/min using a linear gradient of 0 – 40 % 
solvent B from 0 to 40 min, 40 – 100 % from 40 to 45 min. Detection was at 214 nm 
using a Waters 996 PDA detector.  
GC analysis of DMSO, DMS, and DMSO2. 20 µl supernatant from the reaction 
with DMSO was mixed with 980 µl ethanol and then this mixture was analyzed in a GC 
instrument (Agilent). 
 
4.4. Results 
Preparation of mouse MsrA, mouse MsrB2, and yeast fRMsr. To assay for the 
reduction of methylsulfinyl-containing compounds, mouse MsrA, mouse MsrB2, and 
yeast fRMsr were expressed, purified, and assayed for Met-O reduction using DTT as a 
reductant (Fig. 4.1.A,B). Specific activity of mouse MsrA for dabsylated Met-S-SO was 
~ 440 nmol/min/mg, mouse MsrB2 for dabsylated Met-R-SO ~ 300 nmol/min/mg, and 
yeast fRMsr for free Met-R-SO ~ 40 nmol/min/mg. Importantly, all these Msrs reduce 
methylsulfinyl group of Met regardless of stereochemistry and form of substrates. Some 
drugs also contain methylsulfinyl moiety, composed of S-sulfoxide and R-sulfoxide form, 
with various attached molecules. Therefore, it might be possible that those drugs can be 
subjected to reduction by Msrs and furthermore each sulfoxide form can be  
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Fig. 4.5. Ion-spray ionization mass spectrometry analysis of triclabendazole 
sulfoxide reduction by Msrs. A. Triclabendazole sulfoxide reduction by mouse MsrA. 
Triclabendazole sulfoxide appears as m/z: 375.1 and 377.1 and its reduced form 
(triclabendazole) at m/z: 359.1 and 361.1. B. Triclabendazole sulfoxide reduction by 
mouse MsrB2. C. Triclabendazole sulfoxide reduction by yeast fRMsr.  
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Fig. 4.6. Reduction of triclabendazole sulfoxide by Msrs. Reduction of triclabendazole 
sulfoxide by mouse MsrA, mouse MsrB2, and yeast fRMsr was assayed using HPLC. A. 
HPLC analysis of triclabendazole sulfoxide reduction by mouse MsrA in a 
TR/Trx/NADPH-dependent reaction. Triclabendazole sulfoxide was detected with m/z: 
375.2 and 377.2 and its reduced form (triclabendazole) with m/z: 359.2 and 361.2. B. 
HPLC analysis of triclabendazole sulfoxide reduction by mouse MsrB2 in a 
TR/Trx/NADPH-dependent reaction. C. HPLC analysis of triclabendazole sulfoxide 
reduction by yeast fRMsr with TR/Trx/NADPH. D. Specific activities of mouse MsrA, 
mouse MsrB2, and yeast fRMsr for the reduction of triclabendazole sulfoxide in DTT or 
TR/Trx/NADPH-dependent reactions (n = 3). 
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Fig. 4.7. Ion-spray ionization mass spectrometry analysis of sulmazole reduction by 
Msrs. A. Sulmazole reduction by mouse MsrA. Sulmazole is detected with m/z: 288.3 
and its reduced form (sulmazole sulfide) at m/z: 272.3. B. Sulmazole reduction by mouse 
MsrB2. C. Sulmazole reduction by yeast fRMsr. 
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Fig. 4.8. Reduction of sulmazole by Msrs. Reduction of sulmazole by mouse MsrA, 
mouse MsrB2, and yeast fRMsr was assayed following separation of substrate and 
product using HPLC. A. HPLC analysis of sulmazole reduced by mouse MsrA with DTT. 
Sulmazole was identified as compound with m/z: 288.3 and its reduced form (sulmazole 
sulfide) with m/z: 272.3. B. HPLC analysis of sulmazole reduction by mouse MsrB2 with 
DTT. C. HPLC analysis of sulmazole reduction by yeast fRMsr with DTT. D. Specific 
activities of mouse MsrA, mouse MsrB2, and yeast fRMsr for reduction of sulmazole 
using DTT or TR/Trx/NADPH as reductants. All measurements were repeated 3 times 
independently. 
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stereoselectively reduced by Msrs. To investigate this possibility, drugs containing 
methylsulfinyl groups were identified by searching PubChem compound database at 
NCBI (Fig. 4.1.C) and some of them were used to test stereoselective reduction by 
several Msrs. In addition, MsrB1 cysteine mutant (MsrB1-Cys), in which Sec was 
replaced with Cys, was used in reductase assays. 
Reduction of mesoridazine by Msrs. Mesoridazine has a methylsulfinyl group 
linked to phenothiazine (Fig. 4.1.C). This compound is known to be generated from 
thioridazine by a hepatic enzyme, Cyp450 oxidase [123, 124]. Mesoridazine was tested 
as  a  subs t ra t e  for  MsrA,  mMsrB2,  and  yfRMsr  wi th in  DTT-  and  Trx 
reductase/Trx/NADPH (TR/Trx/NADPH)-dependent reactions. We employed two 
methods for detection and quantify the reduced product. Based on the ion-spray mass 
spectrometry analysis, only mMsrA showed an increase in thioridazine (m/z: 371.2), 
whereas there was essentially no change of thioridazine peak in the presence of mMsrB2 
or yfRMsr (Fig. 4.2.). We further examined changes in mesoridazine and thioridazine 
levels using HPLC. Consistent with the ion-spray mass spectrometry data, we found that 
thioridazine (m/z: 371.6) increased rapidly in the presence of mMsrA, but mMsrB2 and 
yfRMsr were inactive (Fig. 4.3.). We carried time course by quantified the product at 
each time point in the reaction with mMsrA (Fig. 4.4.). Specific activity for the reduction 
of mesoridazine was 206.8 ± 45.2 nmol/min/mg in the DTT-dependent assay and 20.2 ± 
3.2 nmol/min/mg with TR/Trx/NADPH (Fig. 4.3.D). Thus, the S-sulfoxide form of 
mesoridazine is reduced specifically by mMsrA, whereas the R-sulfoxide form could not 
be reduced by either mMsrB or fRMsr. Since this drug is used in a mixed R- and S-  
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Fig. 4.9. Reduction of S-sulforaphane-DTT conjugate by mouse Msrs. Reduction of 
S-sulforaphane-DTT conjugate by mouse MsrA and mouse MsrB2 using HPLC. A. 
HPLC analysis of S-sulforaphane-DTT conjugate reduction. S-sulforaphane-DTT 
conjugate was detected at species with m/z: 332.4 and its reduced form (erucin-DTT 
conjugate) with m/z: 316.4. B. HPLC analysis of S-sulforaphane-DTT conjugate 
reduction by mouse MsrB2 with DTT. C. HPLC analysis of S-sulforaphane-DTT 
conjugate reduction by mouse MsrA with DTT.  
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Fig. 4.10. Reduction of DMSO by Msrs. A. A GC analysis of DMSO reduction by 
mouse MsrA with TR/Trx/NADPH. DMS is the reduced form of DMSO. B. GC analysis 
of DMSO reduction by mouse MsrB2 with TR/Trx/NADPH. C. GC analysis of DMSO 
reduction by mouse MsrB1-Cys with TR/Trx/NADPH. D. Specific activities of mouse 
MsrA, mouse MsrB2, and mouse MsrB1-Cys in the reduction of DMSO with 
TR/Trx/NADPH. DMS was not detected in the reactions catalyzed by mouse MsrB2 and 
MsrB1-Cys (n = 3). 
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sulfoxide form (according to the Sigma’s information) and MsrA is specific for the S-
sulfoxide form, we suggest that about half of the drug is metabolized by MsrA to the 
reduced form and the other half could not be reduced in mammals.   
Reduction of triclabendazole sulfoxide and sulmazole by Msrs. We further 
examined two other drugs containing methylsulfinyl groups, triclabendazole sulfoxide 
and sulmazole. Triclabendazole sulfoxide has methylsulfinyl group linked to 
benzimidazole (Fig. 4.1.C) and the reduced form of this drug is known to be oxidized by 
Cyp450 oxidase and flavin-monooxygenase (FMO) in vivo [125, 127]. We first 
investigated this compound for reduction by mMsrA, mMsrB2, and yfRMsr using ion-
spray mass spectrometry. Triclabendazole sulfoxide could be reduced to triclabendazole 
(m/z: 359.1, 361.1) only by mMsrA, but not by mMsrB2 or yfRMsr (Fig. 4.5.). These 
data were also consistent with the results of HPLC analysis. A significant increase in 
triclabendazole (m/a: 359.2, 361.2) was found only in the mMsrA reaction (Fig. 4.6.). 
Specific activity of mMsrA for triclabendazole sulfoxide was 94.8 ± 18 nmol/min/mg in 
the DTT-dependent reaction and 18 ± 2.5 nmol/min/mg in the presence of 
TR/Trx/NADPH (Fig. 4.6.D). Similarly, sulmazole was subjected to the reduction by 
mMsrA, mMsrB2, and yfRMsr. This compound has its methylsulfinyl group linked to 
imidazopyridine (Fig. 4.1.C). Interestingly, it was reported that, when sulmazole was 
injected in animal tissues, its reduced form, sulmazole sulfide, was detected in body 
fluids, such as plasma, urine, and bile [23], suggesting the role of Msr(s) in the reduction 
of this compound. Indeed, we observed the reduction of the sulfoxide group in sulmazole 
by mMsrA, but not by mMsrB2 or yfRMsr. We found a significant increase in the 
reduced form (m/z: 272.3) in the mMsrA-dependent reaction (with DTT as a reductant) in 
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ion-spray mass spectrometry analysis (Fig. 4.7.). We also confirmed and quantified an 
increased amount of sulmazole sulfide in the mMsrA reaction by HPLC (Fig. 4.8.). Its 
specific activitiy for mMsrA was 53.8 ± 4.7 nmol/min/mg in the DTT-dependent reaction 
and 7.1 ± 1.7 nmol/min/mg with TR/Trx/NADPH (Fig. 4.8.D). We also analyzed 
timecourse of triclabendazole sulfoxide and sulmazole reduction (Fig. 4.4.). Overall, 
these analyses revealed that methylsulfinyl-containing drugs can be reduced specifically 
by mMsrA, but not mMsrB2 or yfRMsr, and therefore that only the S-methylsulfinyl 
forms of drugs are reducible in mammals.    
Reduction of sulforaphane by Msrs. We next examined the roles of mMsrA, 
mMsrB2, and mMsrB1-Cys (Cys form of mouse MsrB1) in the reduction of R-
methylsulfinyl and S-methylsulfinyl forms of sulforaphane. In this experiment, we added 
an excessive amount of DTT to form a conjugate with the isothiocyanate group of 
sulforaphane (prior to Msr reaction) because this functional group is highly reactive with 
sulfhydryls [129] and can inhibit Msrs. We then assayed generation of erucin-DTT 
conjugate, which is the reduced form of sulforaphane-DTT conjugate. The sulforaphane-
DTT conjugate was partially converted to erucin-DTT in a non-enzymatic reaction; 
however, when MsrA was added to the reaction mixture, the amount of erucin-DTT was 
higher than in the control (Fig. 4.9.).  
Reduction of dimethylsulfoxide by Msrs. Finally, DMSO was examined as a 
substrate for mMsrA, mMsrB2, and mMsrB1-Cys. This compound has numerous 
applications in research and clinic as solvent for organic molecules. We used GC to 
examine DMSO reduction by Msrs and found that only MsrA reduced this compound, 
whereas mMsrB2 or mMsrB1-Cys were not active (Fig. 4.10.). The specific activity of 
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mMsrA with TR/Trx/NADPH was ~ 28.6 ± 5.73 nmol/min/mg (Fig. 4.10.D). Even 
though DMSO does not have a chiral group at the sulfur atom, this compound is not a 
substrate for MsrBs, whereas MsrA can quantitatively reduce it.  
 
4.5. Discussion 
MsrA and MsrB have the same function in reducing methionine sulfoxide 
residues, but their catalytic efficiency with free methionine sulfoxides is highly different. 
The inability of MsrB to reduce free Met-R-SO can be compensated by fRMsr, a recently 
discovered novel Msr family, but this enzyme is absent in mammals. Like Met, certain 
drugs and natural compounds also may have methylsulfinyl-containing moiety, but it was 
unclear whether these compounds are also subject to stereospecific reduction by MsrA, 
MsrB, or fRMsr. Currently, only sulindac is known for selective reduction by E. coli 
MsrA.  
In our work, we found that the findings with regard to Met sulfoxide could be 
extended to any methylsulfinyl-containing compound. Only MsrA could reduce 
methylsulfinyls, whereas neither MsrB nor fRMsr were active. This selective reduction 
was further confirmed in the reaction with DMSO. DMSO is not a chiral compound, but 
only MsrA exhibited activity with this compound. Accordingly, stereospecificity for S-
sulfoxide and broad substrate specificity of MsrA, i.e., its reduction of any methylsulfinyl, 
should lead to stereospecific reduction of mixtures of S-sulfoxide and R-sulfoxide forms 
of drugs. Mammals have one MsrA and three MsrBs, such as MsrB1, MsrB2, and MsrB3. 
Three MsrBs share nearly identical function, conserved sequence, and probably structure. 
On the contrary to MsrA, protein-based Met-R-SO was the only known substrate for 
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three MsrBs. Our drug assay data support the fact that MsrB has a narrow substrate range 
and thus might not allow it to reduce methylsulfinyl-containing compounds or reduce 
them with extremely low efficiency except protein-based Met-R-SO. Therefore, most S-
sulfoxide form of methylsulfinyl-containing drugs might be stereospecifically reduced by 
MsrA, but R-sulfoxide form of that might not be reduced by any Msrs. Therefore, R-
sulfoxide forms of those drugs might be subject to further oxidation to form sulfone 
without reduction, but S-sulfoxide forms of those drugs might be reduced to sulfide form 
and expert different efficacy. This stereoselective reduction of methylsulfinyl-containing 
drugs has huge potential in its application if difference of efficacy occurs between 
oxidized and reduced form. MsrA and MsrB are ubiquitous enzymes except some 
thermophiles and thus most species might be subject to stereoselective reduction for S-
sulfoxide form of drugs. Thorough understanding of drug metabolism is crucial in the use 
of compounds in clinic. Like natural metabolites, drugs are subject to various reactions, 
with liver being the major organ that activates, inactivates or further metabolizes drugs. 
For example, Cyp450-mediated oxidation has been examined in great detail to understand 
the consequences of adding an oxygen atom to various groups of compounds [120]. 
Certain polymorphisms in Cyp450 genes may cause changes in the response to drugs 
among various ethnic populations [130]. On the other hand, reductive metabolism of 
drugs receives less attention. In this regard, our findings related to the stereospecific 
reduction of methylsulfinyl-containing compounds provides crucial new information 
relevant to the use of such drugs. Oxidation of methylsulfide to methylsulfoxide or the 
corresponding reduction process may lead to changes in hydrophobicity, target binding 
properties, membrane affinity, and many other factors, ultimately affecting drug efficacy 
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and toxicity. Currently, separation of two diastereomers of methylsulfoxide-containing 
drugs is rarely used in treatment because little is known about specificity methylsulfinyl 
reduction. Separating methylsulfinyl containing-drugs into R and S-sulfoxide forms 
should provide new strategies for increased efficacy of these compounds in clinic. 
It was reported that mammalian Msr activity decreases under oxidative stress and 
during aging [39, 133]. This observation poses an additional challenge in the use of 
methylsulfinyl-containing drugs. ROS generation and subsequent oxidative damage 
accumulate with advanced age, while defense systems, including antioxidant enzymes, 
become weakened, resulting in an increased occurrence of cancer, neurodegeneration, 
and many other pathologies. Methylsulfide-containing drugs are also subject to these 
processes, wherein their oxidized forms will be efficiently reduced by MsrA with age.    
Although our study examined only a limited number of methylsulfinyl-containing 
drugs, the overall findings are very clear and should apply to other compounds such as 
enoximone, nifuratel, albendazole, pergolide, lincomycin, triethylperazine, fensulfothion, 
clindamycin, captodiame, flosequinan, thiocolchicoside. Moreover, certain newly 
developed drugs will surely be characterized by this functional group. Based on these 
data, we suggest to test efficacy and efficiency of methylsulfide- (or methylsufoxide-) 
containing drugs in two different forms under physiological conditions and characterize 
their metabolism by MsrA. Then, smart enantiomeric separation of methylsulfoxide-
containing drug can be applied in the advanced use of drugs in humans and animals.   
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CHAPTER 5 
 
Roles of methionine and methionine sulfoxide in aging and reproduction in 
Drosophila melanogaster 
 
Note: The results described in this chapter have been written up for publication. 
The authors and title of the paper are: 
Lee, B.C. and Gladyshev, V. N. (2010) Roles of methionine and methionine 
sulfoxide in aging and reproduction in Drosophila melanogaster, manuscript in 
preparation 
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5.1. Abstract 
Methionine (Met) restriction has been implicated in lifespan extension in various 
organisms by mimicking calorie restriction. However, these analyses are often 
complicated by the requirement to dilute the diet, which modifies the levels of other 
dietary factors. In this work, we employed a chemically-defined diet lacking Met and 
supplemented with graded levels of Met or Met sulfoxides to examine the roles of these 
amino acids in aging in mixed-sex populations of Drosophila melanogaster. This 
approach identified differences in Met requirement to maximize lifespan between 
Canton-S and Oregon-R flies as well as in tolerance to high Met and Met deficiency 
between male and female flies. Both diastereomers of Met sulfoxide supported 
metabolism, but differentially influenced lifespan of male and female flies. Animals 
survived on the diet lacking Met by synthesizing it or reducing Met sulfoxides, and 
dietary Met supplementation further increased its content. Met was a limiting factor for 
egg production, but not for lifespan, a finding that suggested the uncoupling of lifespan 
and fecundity and argued against the idea of reallocation of nutrients for somatic versus 
reproductive functions. Overall, this study established specific roles of Met and Met 
sulfoxides in aging and reproduction in Drosophila.  
 
5.2. Introduction 
Dietary restriction as means of extending lifespan has been used extensively in a 
variety of model organisms, such as yeast, nematodes, fruit flies, rats, and mice [135-
142]. However, the mechanisms and dietary components responsible for this effect 
remain poorly characterized in most of the model systems. In fruit flies, restriction in 
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yeast extract extended lifespan, but sugar restriction was not effective [143, 144], 
suggesting that a specific component of yeast extract is a factor that mediates the effect of 
calorie reduction [143, 144]. It was also reported that Met restriction mimics lifespan 
extension by calorie restriction in mice [145-150], providing one of the first examples of 
how a specific dietary factor could function to extend lifespan [150]. 
Previous calorie and protein restriction experiments revealed that lifespan can be 
regulated by these types of dietary restriction. For such studies in fruit flies, both sugar 
and yeast extract dilution or only dilution of yeast extract were used. However, though 
these regimens have been useful in addressing many questions in the area of aging, they 
have a limitation in that identification of nutritional factors was not possible because one 
cannot remove a component from yeast extract without changing other components [145, 
147]. The use of chemically-defined diets can address this deficiency [147]. Recently, 
Troen et al. developed a chemically-defined diet that can be used to address the role of 
Met on lifespan of fruit flies [151]. They found no changes in mean and maximum 
lifespan of non-virgin females when the diet contained 0.045-0.135% Met and 15% 
glucose. But, the 0.405% Met diet shortened both maximum (2.3%) and mean (9.6%) 
lifespan. Met can be easily oxidized to Met sulfoxide (Met-O) that exists in an 
enantiomeric mixture of methionine-S-sulfoxide (Met-SO) or methionine-R-sulfoxide 
(Met-RO). Met-SO and Met-RO can be reduced back to Met by Msrs, and thus Met-O 
can be used as a source of Met. However, when Met-O replaced Met in cell culture media 
or diet, the growth of mammalian cell lines, rats, and mice was reduced [144, 152, 153].    
Dietary restriction studies have mostly examined aging of males and females 
housed separately to minimize potential influence of mixed-sex populations and egg 
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production on lifespan. It is widely accepted that egg production adversely affects female 
lifespan [154]. Previous studies have also found that lifespan of male and female flies is 
differentially affected by sugar/yeast dietary restriction [155, 156]. In the present study, 
we used chemically-defined diet supplemented with Met or Met-O to examine aging in 
fruit flies. Mixed-sex populations of Drosophila melanogaster were used in order to 
examine interplay between lifespan and fecundity. This work identified relationships 
between dietary Met, egg production, and lifespan, and differences in the effect of Met on 
lifespan of males and females, establishing critical and specific roles of Met in 
Drosophila aging. 
 
5.3. Experimental procedures 
Preparation of free Met-SO and Met-R-SO. Free Met-SO and Met-RO were 
prepared from mixed L-Met-R,S-sulfoxide (Sigma, St. Louis, Missouri, USA) as 
described previously [34]. 
Fly stocks and diets for lifespan experiments. Flies were kept in 25×95 mm 
polystyrene vials at 25 °C on a 12 h light-dark cycle prior to lifespan experiments. A 
basal diet mix (TD.04310) was purchased from Harlan Teklad (Indianapolis, IN, USA) 
and prepared for lifespan studies as described previously [151] with minor modifications. 
Briefly, after boiling 1 L distilled water, 62.08 g basal mix, 500 mg nucleic acids, 100 mg 
lecithin, 22 g agar, 100 g glucose (final concentration 15%) and the appropriate amounts 
of L-Met (0, 0.0224, 0.149, or 1.49 g), L-Met-RO (0.165 g), or L-Met-SO (0.165 g) were 
added with gentle stirring. After temperature slightly decreased, 2.85 ml propionic and 
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0.765 ml phosphoric acids were added. Canton-S and Oregon-R strains were kindly 
provided by Lawrence Harshman (University of Nebraska, Lincoln, NE, USA). 
 Lifespan analysis, egg generation assay, and preparation of flies for Met 
analysis. Newly eclosed adult animals were collected within 4 h and kept on the 
indicated diets at a density of 25 animals per vial. 3-day-old flies were placed in cages for 
lifespan analysis and in 25×95 mm polystyrene vials for Met analysis. 30-35 males and 
30-35 females were kept in each cage and 15 males and 15 females in each vial. Six 
replica cages and vials were simultaneously used for each experimental condition. 
Survivor curves are presented as the average of these independent replicas. Fresh food 
was supplied into cages and vials and dead flies were removed by aspiration. Animals 
were examined and counted every 3 days. Starting from 15 days, eggs generated during 
the previous 24 h were counted until all flies had died in the cage. Animals were 
maintained in a temperature controlled incubator at 25 °C with 12 h light-dark cycle and 
50–60% humidity. 
Met analysis. 24-day-old male and female flies maintained on each diet were 
collected and stored at -70 °C for subsequent Met analysis. They were homogenized in 
liquid nitrogen, resuspended in PBS containing protease inhibitor mixture (Roche, 
Madison, WI, USA), incubated on ice and centrifuged at 16,000 g for 18 min at 4 °C. 
Total protein concentration in supernatant was measured by the Bradford method. 
Samples were diluted to the same protein concentration and stored at -70 °C until used 
for HPLC analysis by OPA deivatization. The derivatization reagent was freshly prepared 
as a stock solution (40 mg of OPA, 1 ml of methanol, 50 µl of 2-mercaptoehanol, 5 ml of 
0.1 M Na2B4O7, pH 9.5) at room temperature in a capped amber vial. Sample solutions (5 
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µl) were mixed with the OPA derivatization reagent to 100 µl final volume. Following a 
2 min reaction at room temperature, 50 µl of the mixture were injected onto a Zorbax 
Eclipse XDB-C18 column (4.6×150 mm) (Agilent, Santa Clara, CA, USA) initially 
equilibrated at room temperature with 20 mM sodium acetate, pH 5.8 (solvent A) and 
methanol (solvent B) at a ratio of 87:13 (v/v). Met was separated from other amino acids 
at room temperature at a flow rate of 1.5 ml/min at the same ratio of solvent A and 
solvent B that was used for column equilibration, using a linear gradient of 13-40% 
methanol (solvent B) from 0 to 5 min, 40-47% methanol (solvent B) from 5 to 40 min, 
and 47-100% methanol (solvent B) from 40 to 45 min. Detection was by fluorescence of 
Met derivatives using a Waters 474 scanning fluorescence detector with excitation at 330 
nm and emission at 445 nm. 
Statistical analysis. The significance of the difference between the survivor 
curves was determined separately for each of 6 replicates of experimental fruit flies on 
each diet using PROC LIFETEST in SAS v. 9.1. This software was also used to obtain 
statistical data for each set of replicates. 
 
5.4. Results 
Mixed-sex fruit fly populations on chemically-defined diets. Mixed sex 
populations of Canton-S and Oregon-R flies were subjected to lifespan analysis on a 
chemically-defined food source, which was composed of amino acids, carbohydrates, 
vitamins, minerals and other defined nutrients that substituted for yeast extract. This diet 
was similar to that previously described [151] except for Met concentrations (Table 5.1.)  
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Table. 5.1. Amino acids composition of the chemically defined diet prior to adding 
Met, Met-SO, or Met-RO. 
Amino acids Concentration (mM) 
L-Aspartic acid 1.88 mM 
L-Glutamic acid 3.8 mM 
L-Serine 2.19 mM 
Glycine 1.33 mM 
L-Histidine 0.51 mM 
L-Arginine 1.83 mM 
L-Threonine 1.76 mM 
L-Alanine 2.92 mM 
L-Proline 1.82 mM 
L-Tyrosine 1.05 mM 
L-Valine 2.56 mM 
L-Cystine 0.42 mM 
L-Isoleucine 1.45 mM 
L-Leucine 2.36 mM 
L-Phenylalanine 1.33 mM 
L-Lysine 3.56 mM 
L-Tryptophan 0.44 mM 
L-Methionine Not included 
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Table. 5.2. Comparison of mean values of Canton-S survivorship for animals on 
chemically defined diets supplemented with Met or Met-O. 
   Canton-S male                          Canton-S female 
Diets 
Mean value 
(Days) 
% change 
Mean value 
(Days) 
% change 
0 mM Met 44.47 ± 0.56 -4.58 40.96 ± 0.56 -15.64 
0.15 mM Met 49.03 ± 0.74 5.21 50.42 ± 0.68 3.84 
1 mM Met 46.60 ± 0.67 RV 48.56 ± 0.57 RV 
1 mM Met-SO 45.08 ± 0.63 -3.26 49.15 ± 0.63 1.22 
1 mM Met-RO 45.45 ± 0.61 -2.46 50.40 ± 0.54 3.80 
10 mM Met 45.34 ± 0.64 -2.71 42.92 ± 0.57 -11.61 
 
*RV: Reference Value 
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Table. 5.3. Comparison of mean values of Oregon-R survivorship for animals on 
chemically defined diets supplemented with Met or Met-O. 
 Oregon-R male Oregon-R female 
Diets 
Mean value 
(Days) 
% change 
Mean value 
(Days) 
% change 
0 mM Met 33.73 ± 0.49 -16.23 36.54 ± 0.36 -19.62 
0.15 mM Met 36.71 ± 0.54 -8.83 39.54 ± 0.56 -13.00 
1 mM Met 40.26 ± 0.50 RV 45.46 ± 0.56 RV 
1 mM Met-SO 35.07 ± 0.45 -12.90 40.31 ± 0.62 -11.32 
1 mM Met-RO 37.85 ± 0.44 -6.00 43.10 ± 0.65 -5.18 
10 mM Met 39.77 ± 0.46 -1.22 40.64 ± 0.51 -10.60 
 
*RV: Reference Value 
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and allowed us to examine the effects of Met and Met-O on lifespan, fecundity and other 
characteristics of fruit flies.  
Differences in Met requirement to maximize lifespan between two strains of 
fruit flies. The use of a chemically-defined diet containing 0.15 mM Met, equivalent to 
Met restriction, showed an increase in lifespan (5.21% in males and 3.84% in females) in 
Canton-S (Table 5.2.), but a decrease (8.83% in males and 13.00% in females) in 
Oregon-R (Table 5.3.) flies, compared with the lifespan of flies maintained on 1 mM Met 
diet (Met-sufficient diet). Thus, Met restriction did not result in consistent lifespan 
changes in fruit flies, in contrast to the observations in rats and mice [145-150]. However, 
analyses of survivorship changes at 0, 0.15, 1, and 10 mM Met revealed the maximum 
lifespan at 0.15 mM in Canton-S and at 1 mM Met in Oregon-R flies (Fig. 5.1., Table 
5.2., and Table 5.3.). Thus, the two strains of fruit flies require different Met levels to 
maximize their lifespan.  
Differential effects of Met-O on lifespan of male and female flies. We further 
tested the diets containing 1 mM Met-RO or Met-SO instead of Met to examine the 
contribution of Msrs to providing Met for metabolic processes in fruit flies. Met-O diets 
fully supported reproduction and lifespan, with the values similar to those observed for 
0.15 mM Met and 1 mM Met diets, which were among the highest of all diets (Fig. 5.1. 
and 5.2.). This data suggested that Met-O provided sufficient levels of Met through its 
reduction by Msrs. On the other hand, we did not observe lifespan extension on either 
Met-O or low Met diets, the conditions previously shown to extend  lifespan in mice 
[145-150].  
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Fig. 5.1. Lifespan of mixed-sex fruit flies maintained on chemically-defined diets. No 
addition of Met (black line), or addition of 0.15 mM Met (red), 1 mM Met (green), 10 
mM Met (orange), 1 mM Met-SO (purple), or 1 mM Met-RO (blue) to the chemically-
defined diet was examined. This experiment used six independent cages for each 
condition and male and female flies were counted every 3 days. (A) Canton-S males. (B) 
Canton-S females. (C) Oregon-R males. (D) Oregon-R females. 
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Difference in tolerance to extreme Met concentrations between male and 
female flies. Higher concentrations of Met (10 mM) were toxic to fruit flies, and they  
differentially affected males and females. Canton-S and Oregon-R male flies were little 
affected by 10 mM Met (compared to the diet containing 1 mM Met), but females had 
significantly lower (11.61% in Canton-S and 10.6% in Oregon-R) lifespan (Tables 5.2. 
and 5.3.). This finding was consistent with the analysis of the accumulative percent 
survival graph, which revealed a shift of the survival curve between 1 and 10 mM Met 
(Fig. 5.1.). Also, different tolerance levels were observed in the case of Met-deficient 
diet. In Canton-S flies, females were much more affected by Met deficiency (compared to 
the 1 mM Met diet) than males (i.e., 15.64% lifespan decrease in females and 4.58% 
lifespan decrease in males). A similar effect was also seen in Oregon-R flies, even though 
the difference was smaller. This data suggests that male and female flies have different 
tolerance to extreme Met concentrations, wherein starvation caused by Met deficiency or 
toxicity due to high Met has a more pronounced effect on females, which require 
increased Met uptake and consumption for protein synthesis in order to generate eggs.  
Met is not essential for survival of Drosophila. The unsupplemented 
chemically-defined diet did not contain Met, its derivatives or protein source. However, 
both male and female flies had a considerable lifespan on this diet (Fig. 5.1.), indicating 
that their minimal demand for Met was met. We also found, in an HPLC analysis, that 
Canton-S flies had significant levels of Met after 24 days on the unsupplemented diet 
(Fig. 5.2.). The difference in Met concentrations was much higher between 1 and 10 mM 
Met than between 0.15 and 1 mM Met in the diet. The data suggest that fruit flies can 
compensate for Met deficiency by synthesizing Met. This finding raises an important  
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Fig. 5.2. Methionine concentration in fruit flies maintained on chemically-defined 
diets. Measurements were done 24 days after flies were provided with the diets 
containing 0, 0.15, 1, or 10 mM Met, 1 mM Met-SO, or 1 mM Met-R-SO. Male (blue 
bar) and female (red) flies were assayed. This measurement was done independently four 
times. 
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Fig. 5.3. Egg production rate of fruit flies maintained on chemically-defined diets. 
No addition of Met (black), or supplementation of the chemically-defined diet with 0.15 
Met (red), 1 mM Met (green), 10 mM Met (orange), 1 mM Met-SO (purple), or 1 mM 
Met-RO (blue) was examined. Egg production was measured every 3 days for 24 h from 
day 15 until day 54. (A) Canton-S females. (B) Oregon-R females. This experiment was 
carried out independently 6 times and the average values were graphed. 
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issue of Met requirement in the design of experiments that examine the effect of Met on 
fruit flies.     
Met is a limiting factor for egg production. Egg production rate was measured 
every 3 days between days 15 and 54 to investigate the relationship between Met 
concentration and reproduction (Fig. 5.3.). In flies on unsupplemented and 0.15 mM Met 
diets, egg generation rate was dramatically lower than that on other four Met diets, 
whereas egg production rate on the 10 mM Met diet was similar to that on the 1 mM Met 
diet. The data show that Met is a limiting factor for reproduction under conditions of Met 
restriction. Importantly, the data suggest that Met deficiency results in the redistribution 
of nutritional sources from egg generation to somatic maintenance, similar to the 
observations of the effect of caloric restriction. The diets supplemented with 1 mM Met-
SO or Met-RO supported fecundity as much as the 1 mM Met diet, providing further 
evidence that Met-O can substitute for Met in the diet. 
Met concentration in fruit flies. We directly analyzed Met in Canton-S flies fed 
the Met diets for 24 days (Fig. 5.2.). Flies supplemented with 0, 1, and 10 mM Met 
showed clear differences in their Met levels. Animals on the 1 mM Met diet had twice as 
much Met as those on the 0.15 mM Met diet, and flies on the 10 mM Met diet had a 
further 5 fold increase compared to the animals on the 1 mM Met diet. However, we 
found no difference between the flies maintained on 0 and 0.15 mM Met diets and also 
no significant difference between flies on 1 mM Met, 1 mM Met-SO, and 1 mM Met-RO 
diets.  
Comparison of average egg production rate and mean accumulative survival. 
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Fig. 5.4. Comparison of mean lifespan and egg production rate values. Mean values 
of male (black line) and female (blue line) lifespan are shown together with egg 
production rate data (red bars). Egg production rate was averaged between days 15 and 
24. (A) Canton-S flies. (B) Oregon-R flies.\ 
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In order to examine interrelationship between fecundity and longevity, we compared 
average egg production rate between 15 and 21 days and mean lifespan of male and 
female flies of Canton-S and Oregon-R backgrounds (Fig. 5.4.). In the case of Canton-S 
females, egg generation rate slightly increased from 0 to 0.15 mM Met, whereas lifespan 
reached an almost maximum level at 0.15 mM Met. In contrast, egg generation rate 
increased dramatically from 0.15 to 1 mM, while lifespan slightly decreased. In addition, 
egg generation rate did not significantly change between 1 and 10 mM Met, but the mean 
lifespan decreased (Figure 5.4.A). In the case of Canton-S males, mean lifespan followed 
the pattern in females, except in between 1 and 10 mM Met. In Oregon-R flies, the 
overall patterns were also similar to those of Canton-S flies (in some cases with a shift as 
discussed earlier). Importantly, increased egg generation did not affect lifespan at 
different Met levels in the diet. Between 0.15 and 1 mM Met, a dramatic increase in egg 
generation occurred in Canton-S flies, but there was essentially no change in the lifespan 
of female flies. In other words, an increase in Met in the chemically defined diet 
contributed to an increase in egg production rate, but this had no influence on lifespan. 
Thus, egg generation and lifespan are not dependent on each other in fruit flies.  
 
5.5. Discussion 
Uncoupling of reproduction and longevity in fruit flies on the Met diets. It is 
thought that nutritional deficiency decreases fecundity and increases lifespan through 
redistribution of nutrient resources, and that food supplies restore egg production leading 
to a reduction in lifespan [154]. However, this idea of the interrelationship between 
longevity and fecundity was not supported by our study that examined the effects of 
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graded amounts of Met and Met-O in a chemically-defined diet on lifespan in Drosophila. 
In particular, lifespan was similar in Canton-S flies maintained on 0.15 and 1 mM Met 
diets, while egg production rate showed more than 7 fold difference, changing from close 
to a minimal value at 0.15 mM Met in the diet and close to a maximal value at 1 mM 
Met. Oregon-R flies showed a similar pattern. These data suggest that fecundity is not a 
significant factor in determining longevity of flies, at least when animals are maintained 
on the chemically-defined Met-supplemented diets.  
Of course, other factors may also be at play in this unexpected relationship 
between longevity and egg production. For example, it is possible that Met levels at or 
below 0.15 mM lead to starvation thereby affecting survival. Indeed, mean lifespan 
decreased when Met was reduced from 0.15 mM to zero, and this also decreased egg 
production rate. However, the starvation effect cannot explain the uncoupling of 
longevity and fecundity because the lifespan at 0.15 mM Met was nearly at a maximal 
level in Canton-S flies. In addition, male flies followed the same survival pattern as the 
one observed in female flies in both Canton-S and Oregon-R strains. In other words, if 
lifespan at 0.15 mM Met was suppressed by starvation in females, lifespan of male flies, 
which were not stressed by egg generation, should have been increased, but it was not.  
Very recently, a study was published that reported that adding Met under 
conditions of dietary dilution increased reproduction, whereas longevity was unchanged 
[158]. Other amino acids were also tested, but had no effect on this uncoupling; 
nevertheless, the Met data argued against the idea of trade-off between reproduction and 
longevity. These findings are fully consistent with our data involving chemically defined 
diets. It was known that Met restriction mimics caloric restriction in extending lifespan of 
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various organisms, suggesting that Met may be an important factor in defining lifespan 
under conditions of caloric restriction. However, this concept should now be 
reconsidered, at least in the case of fruit flies, because Met deficiency reduced 
reproduction but did not increase lifespan. Perhaps, flies use a different mechanism to 
extend lifespan that is not necessarily linked to reproduction. 
Different tolerance to Met deficiency and excess between male and female 
flies. It was reported that a highly concentrated diet had a stronger influence on lifespan 
of female Canton-S flies when mixed populations were examined [157]. We also 
observed a greater variation in longevity in female Canton-S and Oregon-R flies than in 
males at a relatively high concentration of Met in the diet. This is an interesting 
phenomenon because low Met was not effective in increasing lifespan of flies regardless 
of sex and genotype (and did not follow the effect of caloric restriction on lifespan), 
whereas high Met led to lifespan decrease (compared to normal Met diet) with a 
difference between male and female flies, suggesting that tolerance to high Met might 
mimic tolerance to a high calorie diet. Perhaps Met is among the major factors that play a 
role in differential tolerance to a highly concentrated diet in males and females, but not 
for changes in lifespan under conditions of nutritional deficiency. An increase in 
longevity by calorie restriction probably requires other metabolites or rely on other 
metabolic processes. 
The mechanism for differential Met tolerance between male and female flies is 
currently unclear. It is possible that reproduction, which is a major sex difference, 
contributes to this effect. However, our data show that egg production did not increase 
between 1 mM and 10 mM Met diets in Canton-S and Oregon-R females, whereas mean 
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lifespan decreased significantly (Figure 4). Therefore, some other factor might be at play. 
Male and female flies contain similar Met levels in their bodies in all Met dietary 
conditions (Figure 2). This observation suggests that food consumption might not be 
much different between the two sexes even in the high Met in the diet, yet only female 
flies were affected with regard to lifespan by this dietary regimen. Finally, high Met did 
not affect egg production rate in females and mean lifespan in males, even though these 
animals had highly elevated levels of this amino acid in their bodies (Figure 2). 
Therefore, although egg-generating females suffer from high Met, by itself it is not 
sufficient to decrease lifespan of fruit flies.   
Benefits of the use of a chemically defined diet supplemented with various 
concentrations of Met. Our study provided several additional insights on the role of Met 
in metabolism and aging. First, flies survived without supplemented Met in the 
chemically-defined diet. Since Met is essential for protein synthesis, methylation and 
transsulfuration pathways, and other processes, the data suggest that Drosophila 
synthesizes Met for its metabolism. This idea was confirmed by our direct Met analyses, 
which found no difference in Met levels in flies maintained on unsupplemented and 0.15 
mM Met diets, whereas Met levels increased at higher levels of this amino acid in the 
diet. Second, Met-O supported growth and egg production in Drosophila. Therefore, fruit 
fly Msrs must be sufficiently active to supply Met-O-derived Met for metabolic 
processes. Third, we observed differences in tolerance to high Met between male and 
female flies.  
Aging experiments in Drosophila often employ carbohydrates and yeast extract as 
dietary components and these food sources can be diluted to mimic caloric restriction. 
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However, such diets have several limitations. First, dilution makes it difficult to identify 
or distinguish the effects of nutritional factors that regulate lifespan. Second, if food 
toxicity influences lifespan, food dilution might reduce toxicity, resulting in increased 
lifespan. Third, examination of a combination of nutritional factors or removal of specific 
dietary components is not possible, e.g., it is difficult to remove a component from yeast 
extract. Therefore, chemically-defined diet composed of known compounds with known 
concentrations should provide a useful system for advanced aging studies. 
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Table 5.4.  Summary statistics of Canton-S male flies 
     
Quartile estimates 
Fly Diet Sex 
No. 
death 
Mean ± SE 
(Days) 
75th 50th 25th 
Canton-
S 
0 mM Met M 189 44.47 ± 0.56 49.50 46.50 40.50 
Canton-
S 
0.15 mM 
Met 
M 191 49.03 ± 0.74 55.50 49.50 43.50 
Canton-
S 
1 mM Met M 187 46.60 ± 0.67 52.50 49.50 40.50 
Canton-
S 
1 mM Met-
SO 
M 198 45.08 ± 0.63 49.50 46.50 37.50 
Canton-
S 
1 mM Met-
RO 
M 199 45.45 ± 0.61 49.50 49.50 40.50 
Canton-
S 
10 mM Met M 196 45.34 ± 0.64 49.50 46.50 37.50 
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Table 5.5.  Summary statistics of Canton-S female flies 
     
Quartile estimates 
Fly Diet Sex 
No. 
death 
Mean ± SE 
(Days) 
75th 50th 25th 
Canton-
S 
0 mM Met F 187 40.96 ± 0.56 46.50 40.50 37.50 
Canton-
S 
0.15 mM Met F 195 50.42 ± 0.68 55.50 49.50 46.50 
Canton-
S 
1 mM Met F 196 48.56 ± 0.57 52.50 49.50 46.50 
Canton-
S 
1 mM Met-
SO 
F 197 49.15 ± 0.63 55.50 49.50 46.50 
Canton-
S 
1 mM Met-
RO 
F 186 50.40 ± 0.54 55.50 49.50 49.50 
Canton-
S 
10 mM Met F 184 42.92 ± 0.57 46.50 42.00 37.50 
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Table 5.6.  Summary statistics of Oregon-R male flies 
     
Quartile estimates 
Fly Diet Sex 
No. 
death 
Mean ± SE 
(Days) 
75th 50th 25th 
Oregon-
R 
0 mM Met M 196 
33.73 ± 
0.49 
40.50 31.50 28.50 
Oregon-
R 
0.15 mM Met M 202 
36.71 ± 
0.54 
40.50 37.50 31.50 
Oregon-
R 
1 mM Met M 198 
40.26 ± 
0.50 
46.50 40.50 37.50 
Oregon-
R 
1 mM Met-
SO 
M 197 
35.07 ± 
0.45 
40.50 35.50 28.50 
Oregon-
R 
1 mM Met-
RO 
M 202 
37.85 ± 
0.44 
40.50 37.50 35.50 
Oregon-
R 
10 mM Met M 206 
39.77 ± 
0.46 
43.50 40.50 37.50 
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Table 5.7.  Summary statistics of Oregon-R female flies 
     
Quartile estimates  
Fly Diet Sex 
No. 
death 
Mean ± SE 
(Days) 
75th 50th 25th 
Oregon-
R 
0 mM Met F 192 
36.54 ± 
0.36 
40.50 37.50 35.50 
Oregon-
R 
0.15 mM Met F 203 
39.54 ± 
0.56 
46.50 40.50 35.50 
Oregon-
R 
1 mM Met F 203 
45.46 ± 
0.56 
49.50 46.50 40.50 
Oregon-
R 
1 mM Met-
SO 
F 200 
40.31 ± 
0.62 
46.50 40.50 35.50 
Oregon-
R 
1 mM Met-
RO 
F 188 
43.10 ± 
0.65 
49.50 43.50 37.50 
Oregon-
R 
10 mM Met F 201 
40.64 ± 
0.51 
46.50 40.50 37.50 
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Table 5.8.  Maximum, minimum, and median lifespan values of Canton-S male flies 
Diet Maximum Minimum Median 
0 mM Met 58.50 16.50 46.50 
0.15 mM Met 70.50 23.50 49.50 
1 mM Met 64.50 16.50 49.50 
1 mM Met-SO 70.50 13.50 46.50 
1 mM Met-RO 67.50 16.50 49.50 
10 mM Met 67.50 16.50 46.50 
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Table 5.9.  Maximum, minimum, and median lifespan values of Canton-S female 
flies 
Diet Maximum Minimum Median 
0 mM Met 62.5 13.5 40.5 
0.15 mM Met 73.5 13.5 49.5 
1 mM Met 62.5 13.50 49.50 
1 mM Met-SO 70.50 13.50 49.50 
1 mM Met-RO 67.50 13.50 49.50 
10 mM Met 62.50 16.50 42.00 
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Table 5.10.  Maximum, minimum, and median lifespan values of Oregon-R male 
flies 
Diet Maximum Minimum Median 
0 mM Met 46.50 13.50 31.50 
0.15 mM Met 52.50 13.50 37.50 
1 mM Met 58.50 13.50 40.50 
1 mM Met-SO 49.50 13.50 35.50 
1 mM Met-RO 49.50 13.50 37.50 
10 mM Met 52.50 25.50 40.50 
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Table 5.11.  Maximum, minimum, and median lifespan values of Oregon-R female 
flies 
Diet Maximum Minimum Median 
0 mM Met 49.50 16.50 37.50 
0.15 mM Met 52.50 13.50 40.50 
1 mM Met 58.50 16.50 46.50 
1 mM Met-SO 55.50 13.50 40.50 
1 mM Met-RO 58.50 13.50 43.50 
10 mM Met 52.50 16.50 40.50 
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Table 5.12. Test of homogeneity of survival curve between Canton-S male flies 
grown on each diet 
  
Log-Rank Wilcoxon  
Diets for comparison χ2 ρ > χ2 χ2 ρ > χ2 
0 mM Met 0.15 mM Met 37.8096 <.0001 20.2300 <.0001  
0 mM Met 1 mM Met 15.7500 <.0001 6.7800 0.0092  
0 mM Met 1 mM Met-SO 2.7893 0.0949 0.3887 0.533  
0 mM Met 1 mM Met-RO 7.1020 0.0077 2.5049 0.1135  
0 mM Met 10 mM Met 3.6931 0.0546 0.5766 0.4476  
0.15 mM Met 1 mM Met 10.8531 0.001 5.0183 0.0251  
0.15 mM Met 1 mM Met-SO 18.8417 <.0001 13.9007 0.0002  
0.15 mM Met 1 mM Met-RO 16.6577 <.0001 9.3068 0.0023  
0.15 mM Met 10 mM Met 18.7114 <.0001 13.0392 0.0003  
1 mM Met 1 mM Met-SO 5.1117 0.0238 5.4009 0.0201  
1 mM Met 1 mM Met-RO 4.2524 0.0392 3.0976 0.0784  
1 mM Met 10 mM Met 1.9493 0.1627 2.3180 0.1279  
1 mM Met-SO 1 mM Met-RO 0.3008 0.5834 0.6142 0.4332  
1 mM Met-SO 10 mM Met 0.0005 0.9825 0.0001 0.9929  
1 mM Met-RO 10 mM Met 0.3502 0.554 0.8689 0.3513  
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Table 5.13. Test of homogeneity of survival curve between Canton-S female flies 
grown on each diet 
 
Log-Rank Wilcoxon  
Diets for comparison χ2 ρ > χ2 χ2 ρ > χ2 
0 mM Met 0.15 mM Met 116.0602 <.0001 111.8717 <.0001  
0 mM Met 1 mM Met 88.0928 <.0001 98.2706 <.0001  
0 mM Met 1 mM Met-SO 97.5094 <.0001 98.1741 <.0001  
0 mM Met 1 mM Met-RO 127.3595 <.0001 138.7239 <.0001  
0 mM Met 10 mM Met 4.9233 0.0265 6.6570 0.0099  
0.15 mM Met 1 mM Met 10.6940 0.0011 4.2313 0.0397  
0.15 mM Met 1 mM Met-SO 3.3925 0.0655 2.4415 0.1182  
0.15 mM Met 1 mM Met-RO 1.6679 0.1965 0.0472 0.8281  
0.15 mM Met 10 mM Met 81.3741 <.0001 80.8003 <.0001  
1 mM Met 1 mM Met-SO 1.7848 0.1816 0.1555 0.6933  
1 mM Met 1 mM Met-RO 6.0111 0.0142 7.0088 0.0081  
1 mM Met 10 mM Met 52.6678 <.0001 67.1203 <.0001  
1 mM Met-SO 1 mM Met-RO 0.6518 0.4195 4.4613 0.0347  
1 mM Met-SO 10 mM Met 63.6085 <.0001 67.4580 <.0001  
1 mM Met-RO 10 mM Met 85.7426 <.0001 105.1529 <.0001  
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Table 5.14. Test of homogeneity of survival curve between Oregon-R male flies 
grown on each diet 
 
Log-Rank Wilcoxon  
Diets for comparison χ2 ρ > χ2 χ2 ρ > χ2 
0 mM Met 0.15 mM Met 20.4160 <.0001 18.6703 <.0001  
0 mM Met 1 mM Met 74.4499 <.0001 76.1828 <.0001  
0 mM Met 1 mM Met-SO 1.4712 0.2252 4.9254 0.0265  
0 mM Met 1 mM Met-RO 28.7566 <.0001 37.4936 <.0001  
0 mM Met 10 mM Met 68.5414 <.0001 67.3269 <.0001  
0.15 mM Met 1 mM Met 20.3038 <.0001 20.1958 <.0001  
0.15 mM Met 1 mM Met-SO 12.8125 0.0003 6.8880 0.0087  
0.15 mM Met 1 mM Met-RO 0.3777 0.5389 1.7548 0.1853  
0.15 mM Met 10 mM Met 16.9993 <.0001 14.1687 0.0002  
1 mM Met 1 mM Met-SO 62.1207 <.0001 55.2436 <.0001  
1 mM Met 1 mM Met-RO 16.1610 <.0001 11.9429 0.0005  
1 mM Met 10 mM Met 0.3137 0.5754 0.6966 0.4039  
1 mM Met-SO 1 mM Met-RO 18.8443 <.0001 19.7335 <.0001  
1 mM Met-SO 10 mM Met 52.4467 <.0001 43.7082 <.0001  
1 mM Met-RO 10 mM Met 11.4262 0.0007 6.0144 0.0142  
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Table 5.15. Test of homogeneity of survival curve between Oregon-R female flies 
grown on each diet 
 
Log-Rank Wilcoxon  
Diets for comparison χ2 ρ > χ2 χ2 ρ > χ2 
0 mM Met 0.15 mM Met 50.8225 <.0001 27.5251 <.0001  
0 mM Met 1 mM Met 181.1156 <.0001 148.1525 <.0001  
0 mM Met 1 mM Met-SO 65.3254 <.0001 37.9679 <.0001  
0 mM Met 1 mM Met-RO 107.4610 <.0001 74.2662 <.0001  
0 mM Met 10 mM Met 62.6788 <.0001 40.9506 <.0001  
0.15 mM Met 1 mM Met 62.7935 <.0001 51.3049 <.0001  
0.15 mM Met 1 mM Met-SO 4.3118 0.0378 1.8717 0.1713  
0.15 mM Met 1 mM Met-RO 31.1454 <.0001 18.4711 <.0001  
0.15 mM Met 10 mM Met 2.6620 0.1028 1.4728 0.2249  
1 mM Met 1 mM Met-SO 38.4022 <.0001 31.9485 <.0001  
1 mM Met 1 mM Met-RO 5.2359 0.0221 5.7740 0.0163  
1 mM Met 10 mM Met 43.5385 <.0001 37.9598 <.0001  
1 mM Met-SO 1 mM Met-RO 15.3381 <.0001 9.0885 0.0026  
1 mM Met-SO 10 mM Met 0.2668 0.6055 0.0432 0.8354  
1 mM Met-RO 10 mM Met 18.4699 <.0001 10.7104 0.0011  
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Table 5.16. Egg production rate of Canton-S female flies on each day (No. 
eggs/female/day) 
Day 0 mM Met 
0.15 mM 
Met 
1 mM Met 
1 mM Met-
SO 
1 mM Met-
RO 
10 mM 
Met 
15 
0.081 ± 
0.050 
0.249 ± 
0.094 
1.387 ± 
0.244 
1.614 ± 
0.427 
1.325 ± 
0.084 
1.151 ± 
0.156 
18 
0.035 ± 
0.045 
0.106 ± 
0.056 
0.925 ± 
0.161 
0.741 ± 
0.171 
0.795 ± 
0.135 
0.648 ± 
0.134 
21 
0.032 ± 
0.046 
0.031 ± 
0.030 
0.614 ± 
0.161 
0.474 ± 
0.052 
0.542 ± 
0.091 
0.477 ± 
0.115 
24 
0.005 ± 
0.008 
0.019 ± 
0.017 
0.376 ± 
0.070 
0.308 ± 
0.055 
0.390 ± 
0.049 
0.337 ± 
0.054 
27 
0.003 ± 
0.005 
0.002 ± 
0.004 
0.262 ± 
0.064 
0.282 ± 
0.059 
0.296 ± 
0.055 
0.277 ± 
0.067 
30 TEP TEP 
0.172 ± 
0.036 
0.166 ± 
0.041 
0.187 ± 
0.045 
0.113 ± 
0.038 
33   
0.112 ± 
0.034 
0.111 ± 
0.021 
0.151 ± 
0.035 
0.097 ± 
0.038 
36   
0.106 ± 
0.029 
0.078 ± 
0.029 
0.134 ± 
0.027 
0.080 ± 
0.044 
39   
0.107 ± 
0.049 
0.069 ± 
0.036 
0.125 ± 
0.042 
0.076 ± 
0.059 
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42   
0.099 ± 
0.056 
0.076 ± 
0.056 
0.080 ± 
0.029 
0.069 ± 
0.024 
45   
0.074 ± 
0.042 
0.070 ± 
0.036 
0.072 ± 
0.045 
0.020 ± 
0.019 
48   
0.049 ± 
0.051 
0.025 ± 
0.022 
0.025 ± 
0.030 
0.046 ± 
0.053 
51   
0.037 ± 
0.052 
TEP 
0.013 ± 
0.020 
0.025 ± 
0.039 
54   TEP  TEP TEP 
TEP: Termination of egg production 
* This experiment was independently repeated 6 times. 
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Table 5.17. Egg production rate of Oregon-R female flies on each day (No. 
eggs/female/day) 
Day 0 mM Met 
0.15 mM 
Met 
1 mM Met 
1 mM Met-
SO 
1 mM Met-
RO 
10 mM 
Met 
15 
0.046 ± 
0.021 
0.182 ± 
0.105 
1.146 ± 
0.062 
0.549 ± 
0.106 
0.969 ± 
0.157 
0.941 ± 
0.176 
18 
0.017 ± 
0.017 
0.039 ± 
0.025 
0.531 ± 
0.089 
0.317 ± 
0.073 
0.595 ± 
0.121 
0.428 ± 
0.101 
21 
0.010 ± 
0.006 
0.021 ± 
0.017 
0.468 ± 
0.110 
0.296 ± 
0.111 
0.510 ± 
0.091 
0.236 ± 
0.095 
24 
0.010 ± 
0.009 
0.019 ± 
0.014 
0.286 ± 
0.039 
0.238 ± 
0.090 
0.397 ± 
0.071 
0.119 ± 
0.050 
27 
0.003 ± 
0.008 
0.009 ± 
0.008 
0.226 ± 
0.044 
0.177 ± 
0.121 
0.287 ± 
0.067 
0.086 ± 
0.026 
30 TEP 
0.002 ± 
0.004 
0.147 ± 
0.048 
0.096 ± 
0.063 
0.126 ± 
0.026 
0.030 ± 
0.020 
33  TEP 
0.109 ± 
0.041 
0.063 ± 
0.028 
0.060 ± 
0.031 
0.011 ± 
0.009 
36   
0.083 ± 
0.042 
0.050 ± 
0.031 
0.044 ± 
0.023 
TEP 
39   
0.073 ± 
0.030 
0.066 ± 
0.082 
0.049 ± 
0.075 
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42   
0.054 ± 
0.072 
0.008 ± 
0.019 
0.021 ± 
0.040 
 
45   TEP TEP 
0.019 ± 
0.034 
 
48     TEP  
TEP: Termination of egg production 
* This experiment was independently repeated 6 times. 
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CHAPTER 6 
 
Conclusions and Future Directions 
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6.1. Conclusions 
 
 Since the initial discovery of MsrA in E. coli, numerous studies showed the 
importance of methionine sulfoxide reductases in cellular defense against oxidative 
stress. For aerobic organisms, ROS generation is inevitable and thus these organisms 
require protective systems, including Msrs. Met is highly susceptible to oxidation, 
resulting in a diastereomeric mixture of Met-S-SO and Met-R-SO. Met oxidation may 
disturb protein structure and function whereas the combined action of MsrA and MsrB 
repairs oxidized proteins and scavenges ROS through reversible formation of Met 
sulfoxides. 
 Besides these two Msr types, our study functionally characterized a new Msr 
enzyme, fRMsr, which was first reported in E. coli in 2007. This protein reduces free 
Met-R-SO, but not free Met-S-SO, or protein-based sulfoxides. Based on our structural 
modeling of this enzyme, its substrate binding pocket is narrow and can only fit free Met-
R-SO. fRMsr has three conserved Cys, including catalytic and resolving residues. This 
enzyme evolved from a family of GAF-domain containing proteins and exists only in 
unicellular organisms. We demonstrated that this enzyme is indeed responsible for the 
reduction of Met-R-SO in yeast cells and nicely completes the Met sulfoxide reduction 
pathway.    
 MsrA and MsrB showed clear difference with regard to catalytic efficiency in 
reducing free Met sulfoxides, even though both of them are efficient reductases for 
protein-bound Met sulfoxides. This discrepancy led to a growth defect of mammalian 
cells on free Met-R-SO, whereas these cells grew normally on free Met-S-SO. Also, 
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significant accumulation of free Met-R-SO was detected in mouse blood, but we detected 
no free Met-S-SO. Importantly, this deficiency was recovered by transfection of yeast 
fRMsr into mammalian cells, which was further confirmed by proliferation assay and 
expression analyses of CBS and ATF3, proteins that are regulated by Met availability. 
However, it is still unclear what the physiological importance of accumulation of single 
Met sulfoxide species is in mammals. Also, the consequences of differential catalytic 
properties of MsrA and MsrB in the reduction of Met sulfoxides remains to be 
investigated. To address these questions, we carried out a study that examined the 
reduction of drugs and other compounds containing a methylsulfinyl moiety.  
 Sulindac is one such methylsulfinyl-containing drug that was previously subjected 
to stereoselective reduction by E. coli MsrA, but not MsrB. In our study, we tested the 
ability of mouse MsrA, mouse MsrB2, mouse MsrB1 and yeast fRMsr to reduce various 
methylsulfinyl-containing compounds. Interestingly, all of them (mesoridazine, 
triclabendazole sulfoxide, sulmazole could be reduced only by mouse MsrA enzyme, but 
not by any other Msrs. Athough these compounds (except sulforaphane) were used in the 
form of a mixture of S-sulfoxide and R-sulfoxide, the fact of the selective reduction by 
MsrA provided evidence that only the S-sulfoxide forms of them were reduced by this 
enzyme. In the case of sulforaphane, S-sulfoxide and R-sulfoxide forms were separately 
tested and the reduction was only detected in the case of S-sulfoxide and MsrA. In 
addition, DMSO was also reduced by MsrA. These results strongly support the idea that 
methylsulfinyl-containing drugs are stereoselectively reduced by MsrA, but not by any 
other Msr enzymes. Furthermore, our data provide the basis for developing advanced 
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drugs characterized by methylsulfinyl stereochemistry, which would be especially critical 
when sulfoxidation or methylsulfinyl reduction affect drug efficiency.   
 Finally, we investigated a correlation between longevity and Met concentration in 
the diet. It was known that Met restriction may extend lifespan in mouse. Based on this 
fact, we applied this dietary treatment to fruit flies, a model of aging that offered us an 
opportunity to examine many dietary conditions. However, we did not observe any 
difference in lifespan when Met sulfoxide diet and Met restriction were applied. Instead, 
we observed uncoupling between longevity on the Met diet and reproduction. A common 
theory of aging suggests that caloric restriction contributes to increased longevity and 
decreased fecundity through redistribution of resources between reproduction and 
somatic maintenance. In other words, it was proposed that reproduction is inversely 
proportional to longevity. However, our Met dietary studies did not agree with this model. 
Therefore, it will be of interest to determine which molecular mechanisms are involved in 
these processes. In addition, we found that female and male flies had different resistance 
to extreme Met concentrations (both low and high met levels). Perhaps Met consumption 
for egg production is responsible for the observed effect on females.   
 Previous functional Msr studies have mainly focused on the reduction of Met 
sulfoxide in proteins, whereas the reduction of free Met sulfoxide received less attention. 
In the present study, we characterized yeast fRMsr homolog, uncovered deficiency in the 
reduction of free Met sulfoxides in mammals, and extended this finding to the design of 
methylsulfinyl-containing drugs with improved efficacy. Finally, dietary studies in fruit 
flies involving Met diets offered insights into basic mechanisms of aging and 
reproduction and questioned a link between these processes.   
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6.2.    Future directions 
 
It was shown that overexpression of several antioxidant enzymes, such as catalase 
and superoxide dismutase (SOD), increase lifespan in some organisms due to an 
antioxidant effect of these enzymes. Similarly, overexpression of MsrA in the nervous 
system of fruit flies lead to 70 % increase in their lifespan. It was also reported that 
deletion of the MsrA gene in several organisms reduced lifespan. On the other hand, the 
effect of MsrB deletion and overexpression is less obvious or has no influence on 
longevity. In our lab, overexpression of several MsrBs, including mouse MsrB2, mouse 
MsrB1, and fruit fly MsrB, was examined in Drosophila, but these proteins did not 
significantly affect lifespan of fruit flies. Accordingly, a critical question is the basis for 
differences in the roles of MsrA and MsrB in lifespan.    
MsrA and MsrB have the same function reducing Met sulfoxide to Met, but they 
have different specificity for reduction of free Met sulfoxides and this difference might 
be responsible for the differential effect of these enzymes on lifep span. Based on this 
hypothesis, we propose to investigate several targeted ideas, which may result in lifespan 
extention in fruit flies. First, Met is involved in TOR signaling, which is known for 
sensing nutrient levels and redox status. This process also intimately linked to regulation 
of the aging process. Second, Met is an indispensible amino acid and is required for basic 
Met-based metabolism, e.g., it is a precursor of GSH, taurine, and Cys. In the case of 
GSH, it was reported that this compound had influence on regulation of the aging process. 
Third, amino acid metabolism generally occurs in mitochondria where much of ROS is 
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formed. Therefore, Met may have a protective effect in this compartment through 
reversible Met sulfoxide formation. These considerations suggest that reduction of free 
Met sulfoxides can be a key regulator of the aging process and should be examined in 
future studies.      
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